Services Agreement - ActaMed Corp. and SmithKline Beecham Clinical Laboratories Inc.
SERVICES AGREEMENT
This SERVICES AGREEMENT (the "Services Agreement" or "Agreement")
is made and entered into as of December 31, 1997 by and between ACTAMED
CORPORATION, a Georgia Corporation ("ActaMed") and SMITHKLINE BEECHAM CLINICAL
LABORATORIES, INC., a Delaware Corporation ("SBCL").
BACKGROUND
ActaMed is in the business of providing electronic data interchange
products and services to the health care industry, including its ProviderLink
software, and desires to develop business involving automated laboratory order
entry and results reporting services.
SBCL provides laboratory testing services to certain Providers
who use SBCL Software (as defined in the License Agreement) for electronic
clinical laboratory test order entry and/or test result reporting between an
SBCL Lab and such Provider. In addition, SBCL uses the SBCL Software to
allow [*] to send laboratory test orders entered electronically to an SBCL
Lab and/or to have the test results reported electronically back to the PSC
or the Provider ordering the test.
The parties previously entered into the Development Agreement
pursuant to which ActaMed and SBCL are jointly developing the ActaLab Software.
Simultaneously with the execution of this Agreement, ActaMed and
SBCL are entering into the Purchase Agreement pursuant to which ActaMed is
purchasing and SBCL is selling certain assets associated with SBCL's provision
of Lab EDI Services, as more fully set forth therein. Also concurrently with
the execution and delivery of this Agreement, SBCL and ActaMed are entering into
the License Agreement whereby SBCL, among other things, grants ActaMed a license
to the SBCL Software. This Agreement sets forth the parties' agreements
relating to their rights and obligations following the date hereof relating to
provision of Lab EDI Services to Automated Providers.
Pursuant to the Purchase Agreement, the Parties contemplate that
there will be a staged transfer to ActaMed of SCAN Assets. The transfer of
Region One SCAN Assets is to occur on the Region One Transfer Date. The
transfer of the other Regions will occur sequentially when the Transfer
Benchmarks (as defined in the Purchase Agreement) have been met.
NOW THEREFORE, in consideration of the premises and the mutual
promises contained herein, the parties, intending to be legally bound, agree as
follows:
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
<PAGE>
I. DEFINITIONS.
Capitalized terms used in this Agreement and not otherwise defined
herein are defined in EXHIBIT A attached hereto.
II. NETWORK READINESS SERVICES.
A. GATEWAY REPLICATION. SBCL shall be responsible [*] to provide
such reasonable and appropriate software development, installation and
support services as are necessary to establish connectivity with an ActaMed
gateway (the "ACTAMED GATEWAY") that works substantially as the SBCL gateway
works as of the date hereof. In connection with such services from SBCL:
1. ActaMed shall [*] order, acquire, install and configure
the necessary hardware and data communications lines required to install and
operate the appropriate gateway systems, including without limitation a [*]
modems, 800 phone service, [*] and data communications lines for connection
to SBCL systems. SBCL will provide specifications and guidance to assist
ActaMed in this effort.
2. SBCL will install the gateway software on ActaMed's computer
and modify the gateway software as necessary to cause it to communicate with the
SBCL systems. At SBCL's determination, this may include new enhancements or
additional software as needed to allow the ActaMed Gateway to transmit
Transmittal Information for Automated Providers using the SCAN Network.
3. At such time as the ActaMed Gateway has been adequately (in
SBCL's determination) tested, including for compliance with applicable SBCL
internal standards and using SBCL sample clinical laboratory test orders and/or
test result report data, in which testing ActaMed and SBCL shall cooperate, SBCL
shall so notify ActaMed. For a period of up to thirty (30) days after the date
of such notice, ActaMed shall be entitled to perform such quality assurance
testing as it shall reasonably deem appropriate. SBCL shall provide reasonable
assistance to ActaMed in this process. If the system is not performing
substantially the same as SBCL's gateway and as necessary to enable ActaMed to
meet the Key Performance Standards and to provide the Lab EDI Services using the
ActaMed Gateway, ActaMed shall provide timely notice to SBCL of such deficiency
or performance problem within such thirty (30) day period. SBCL shall supply
the appropriate personnel to investigate and correct any such reported
deficiencies or performance problems. The acceptance period shall be extended to
two (2) weeks beyond the time of such correction. When corrected to the
reasonable satisfaction of ActaMed and SBCL, or if SBCL is notified of no
further deficiencies or performance problems within such period, the ActaMed
Gateway shall be deemed ready and accepted by ActaMed.
4. SBCL will provide reasonable training of ActaMed personnel and
any available documentation to allow ActaMed to operate and support its gateway
independently;
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-2-
<PAGE>
provided that SBCL will not provide [*] or other base-line training that may
be required by ActaMed.
5. The foregoing procedures of this Section II.A shall be
completed within one hundred twenty (120) days after the date hereof.
6. After acceptance of the ActaMed Gateway and until [*] SBCL
shall, at ActaMed's written request, provide such maintenance and related
support to the ActaMed Gateway as may be necessary to continue its effective
operation at substantially the same performance levels as SBCL experienced on
its gateway immediately prior to the date hereof. SBCL shall charge ActaMed
for such services at the then industry standard rates for similar services.
After [*] (i) SBCL makes no representation or warranty as to the performance
of the ActaMed Gateway software systems so established by SBCL hereunder; and
(ii) ActaMed may request SBCL to provide such support and, if SBCL elects to
provide such support, SBCL may charge ActaMed for such services at the then
industry standard rates for similar services.
B. MIGRATION PERIOD. After the Transfer Date of a Region, SBCL and
ActaMed shall have the following obligations with respect to SBCL Sites
transferred to ActaMed in that Region:
1. ACTAMED TO MIGRATE SITES. ActaMed will use its good faith
efforts to migrate the SBCL Sites so transferred from communicating with the
SBCL gateway to communicating with the ActaMed Gateway as soon as practicable,
and shall similarly use its best efforts, and take all steps reasonably
necessary, to assign financial responsibility or otherwise change the billing of
dedicated phone lines installed in Automated Providers' offices for Lab EDI
Services from SBCL over to ActaMed. SBCL will support ActaMed in ActaMed's
efforts to transfer the local phone lines to ActaMed's account and, subject to
ActaMed's obligation under Section II.B.7.(g) hereof, pay any charges,
assessments, fees or other amounts incurred by SBCL for such transfer.
2. EDI AGREEMENT AMENDMENTS. ActaMed shall obtain signed
amendments to any existing CIS Agreement between a Provider and SBCL or a new
CIS Agreement between the Provider and ActaMed containing the provisions set
forth in EXHIBIT II.B.2(a). SBCL shall obtain a signed agreement from such
Provider for Lab EDI Services by ActaMed in the form of EXHIBIT II.B.2(b).
3. ASSISTANCE FROM SBCL. SBCL will make available to ActaMed
such resources as SBCL determines is reasonable and appropriate for the
transfer of each Region, at no cost to ActaMed. After the earlier of (i) [*]
after the Transfer Date for a particular Region or (ii) the full migration of
SBCL Sites in such Region from communication with the SBCL gateway to
communication with the ActaMed Gateway, SBCL will continue to use its good
faith efforts to make such resources available to ActaMed and may charge
ActaMed therefor at then industry standard rates for similar services.
4. SUPPORT SERVICES. From time to time prior to the [*]
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-3-
<PAGE>
a. ActaMed may request that SBCL's [*] provide services
to ActaMed in [*] to assist ActaMed in the delivery of items relating to
ActaMed's delivery of Lab EDI Services to Automated Providers (provided
ActaMed delivers the item to [*] for such delivery to the Automated
Provider), such services to be provided consistently with the manner and
extent to which SBCL has used such [*] during the twelve (12) month period
prior to the Transfer Date of the Region in [*] is located. SBCL shall
direct its [*] to provide such services provided that SBCL shall not be
responsible for any Losses incurred as a result of providing such services.
Nothing in this Section III.B.4 shall require SBCL, ActaMed or [*] to provide
any service if to do so would cause any party, including [*] to violate any
Regulation.
b. SBCL may request that ActaMed's employees provide
services to SBCL in the course of their normal duties to assist SBCL in the
delivery of items (E.G., [*]) to Automated Providers (provided SBCL delivers
the item to the employee for such delivery to the Automated Provider), such
services to be provided consistently with the manner and extent to which SBCL
has used employees for such purposes during the twelve (12) month period
prior to the Transfer Date of the Region in which such employee works.
ActaMed shall direct its employees to provide such services provided that
ActaMed shall not be responsible for any Losses incurred as a result of
providing such services. Nothing in this Section III.B.4 shall require
ActaMed, SBCL or such employee to provide any service if to do so would cause
any party, including the respective employee, to violate any Regulation.
5. USE OF SBCL FACILITIES BY TRANSFERRED EMPLOYEES. ActaMed
will employ the Transferred Employees in accordance with the provisions of
Article VI of the Asset Purchase Agreement. From the Transfer Date of a
Region until [*] after the Transfer Date of that Region, such Transferred
Employees may continue to use such office space, office equipment, office
telephones, office supplies, and have access to such office services as such
Transferred Employees had immediately prior to the applicable Transfer Date
(collectively, "OFFICE SPACE"), [*] whether or not such Transferred
Employees are responsible for ActaMed Sites. No employees of ActaMed other
than the Transferred Employees currently assigned to such Office Space shall
be allowed to use such Office Space, and ActaMed may not place signage inside
or outside of such Office Space or use such Office Space for any operations
other than the transition contemplated by this Section II and the provision
by ActaMed of Lab EDI Services.
6. SCAN NETWORK MAINTENANCE. SBCL shall continue to have and
support Lab EDI Services between each SBCL Site and SBCL's gateway until
migration of such SBCL Site to the ActaMed Gateway is completed. SBCL will
continue to operate and maintain its gateway systems for such purposes.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-4-
<PAGE>
7. ACTAMED PAYMENTS TO SBCL. In consideration of services
provided under this Agreement, ActaMed will pay SBCL the following amounts (in
addition to any other amounts which may be charged to ActaMed by SBCL as
expressly set forth in this Agreement):
a. A fee in the amount of [*] per month for each month
after the Region One Transfer Date (prorated for any portion thereof);
provided that no payment shall be made under this clause a. either (i) if a
payment is made under clause b. below, after the third month after the Region
One Transfer Date, or (ii) if a payment is not made under clause b. below,
after the Region Two Transfer Date.
b. A fee in the amount of [*] for each month prior to the
Region Two Transfer Date (prorated for portion thereof) commencing with the
fourth month after the Region One Transfer Date, provided, however, that
payment under this Section II.B.7.b shall not be made unless the delay in the
Region Two Transfer Date beyond the date three (3) months after the Region
One Transfer Date is due to ActaMed's failure to meet the Transfer Benchmarks
(with any dispute with respect thereto to be resolved in accordance with
Section XV hereof).
c. A fee in the amount of [*] per month for each month
after the Region Two Transfer Date (prorated for any portion thereof),
provided that no payment shall be made under this clause c. after the Region
Three Transfer Date;
d. A fee in the amount of [*] per month after the Region
Three Transfer Date (prorated for any portion thereof), provided that no
payment shall be made under this clause d. after the Region Four Transfer
Date;
e. Until the date which is twelve (12) months after the
Transfer Date of a Region, reimbursement for any local and long distance
telecommunication services (including 800 and 888 service other than 800 and
888 numbers used to [*]) billed to SBCL in respect of SBCL Sites in that
Region;
f. From and after the date which is twelve (12) months
from the Transfer Date of a Region, an amount equal to [*] of the amount of
any local and long distance telecommunication services (including 800 and 888
service other than 800 and 888 numbers used to [*]) billed to SBCL in respect
of SBCL Sites in that Region; and
g. Reimbursement for [*] of any charges, assessments, fees
or other amounts incurred by SBCL for the transfer of any dedicated phone
lines installed in Automated Providers' offices for Lab EDI Services into the
ActaMed name, including without limitation any transfer fees or new
installation fees.
C. PAYMENT TERMS FOR ACTAMED PAYMENTS TO SBCL. SBCL shall invoice
ActaMed monthly for the services rendered by it and chargeable to, or to be
reimbursed by, ActaMed pursuant to this Section II. All amounts shown due on
such invoice shall be paid within [*] after the date of the invoice. Late
payments shall be subject to a late fee equal to [*] per
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-5-
<PAGE>
month on the overdue amount. In the event ActaMed disputes any amount shown
due on such invoice, ActaMed shall pay timely any undisputed amounts and send
a Dispute Notice to SBCL with respect to any disputed amounts. For a period
of thirty (30) days after the date of the Dispute Notice, ActaMed shall have
Audit Rights with respect to the portions of SBCL's books and records that
relate to the subject of the dispute. In the event the parties are unable to
resolve the disputed matter, the matter shall be resolved in accordance with
Section XV hereof and application of any late fee to such disputed amount
shall be tolled until conclusion of such proceedings and then applied only to
the amount so determined to be due.
III. SERVICES AFTER TRANSFER.
A. PLANNING AND OVERSIGHT COMMITTEE. On or promptly after the Region
One Transfer Date, SBCL and ActaMed will establish an Oversight Committee having
the obligations set forth in this Section III (the "OVERSIGHT COMMITTEE"). The
parties may thereafter, in their respective sole discretion, change the
complement of the Oversight Committee, including without limitation to decrease
or increase the number of members on the Oversight Committee, so long as the
Oversight Committee shall continuously have equal numbers of persons
representing ActaMed and SBCL, provided that SBCL may appoint a majority of the
Oversight Committee members if ActaMed consents thereto. The Oversight Committee
shall continue in effect through the term of the Agreement (including any
applicable renewal period). Each member of the Oversight Committee will have
responsibility to, among other things,
1. review the performance of ActaMed hereunder, as measured by
the Performance Standards,
2. review the compliance of ActaMed with Regulations and report
to ActaMed and SBCL with respect to compliance matters,
3. discuss trends in the health care information services
industry and service type and quality offered by competitors of ActaMed,
4. exchange information regarding strategic needs and directions
of the respective ActaMed and SBCL businesses that are relevant to the
relationships contemplated by this Agreement,
5. exchange information about technological developments for
electronic connectivity in the health care information services industry,
6. provide feedback to ActaMed and SBCL regarding the
implementation and effect of ActaMed's preferred provider status pursuant to
Section VII of this Agreement,
7. notify SBCL, ActaMed and other members of the Oversight
Committee at any time such member has any knowledge that ActaMed has not
performed in accordance with the Performance Standards, and make recommendations
to ActaMed and SBCL as to remedying
-6-
<PAGE>
performance that does not comply with this Agreement, including without
limitation the Performance Standards, and
8. examine and, collectively with the other members, report to
ActaMed and SBCL from time to time on ways in which Agreed Services can be
improved.
B. AGREED SERVICES. ActaMed will provide the following services to
SBCL and Automated Providers at ActaMed Sites in accordance with the Performance
Standards and will take all reasonable and appropriate action to preserve the
Network and the goodwill of the Automated Providers utilizing such services:
1. NETWORK SUPPORT. ActaMed shall maintain and support the
Network for Lab EDI Services between Automated Providers and an SBCL Lab and
shall ensure that the Network meets or exceeds all Network Standards.
2. INSTALLATION AND TRAINING. ActaMed will provide
installation, set up and training services at all ActaMed Sites as reasonably
necessary to enable such ActaMed Sites to utilize the Network accurately and
efficiently. In this connection, ActaMed will (i) install software, and if
necessary and appropriate and consistent with contractual relationships
between SBCL and ActaMed, hardware, (ii) confirm set up thereof, (iii)
confirm the ability after set up to successfully transmit and receive modem
communications with the applicable SBCL Lab and that requisitions and results
functionality is accurate, and (iv) provide competent and timely training to
the Automated Provider's personnel regarding Lab EDI Services. Such
installation, set up and training services shall be provided to, and
connectivity to the Network established for, any Provider or PSC designated
by SBCL. If ActaMed identifies a Provider which is a potential new customer
for Lab EDI Services, it shall so notify SBCL and SBCL shall determine if
such installation, set up and training services shall be provided to such
Provider. SBCL and ActaMed shall [*] to establish [*] to provide guidance on
[*] of ActaMed suggested Automated Providers. Prior to any
installation, set up and training services being rendered hereunder, SBCL and
ActaMed shall have each entered into an agreement for such Lab EDI Services
with such new customer which agreement shall contain the provisions set forth
on EXHIBIT II.B.2(b).
3. SPECIAL SERVICES AT PIF SITES. At up to [*] (the "PIF
NUMBER") sites selected by SBCL prior to the [*] [*] where
installation training and set up services are required (the "PIF SITES"),
SBCL shall be entitled, by written request to ActaMed and payment of the [*]
set forth in Section IV.B.2, to require that installation, set up and
training services be provided on a top priority accelerated basis.
4. INITIAL ROLL OUT OF ACTALAB SOFTWARE. After market launch of
the ActaLab Software (which shall be only after the ActaLab Software functions,
features and performance have been accepted by SBCL in accordance with the
Development Agreement and the requirement in this Agreement that it comply with
Regulations), ActaMed will begin to replace the SCAN Software at ActaMed Sites
with the ActaLab Software in accordance with a roll out plan developed by
ActaMed
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-7-
<PAGE>
which shall be designed to deploy the ActaLab Software as quickly as
practicable with minimal disruption to Automated Providers. ActaMed shall
submit the roll out plan to SBCL sufficiently in advance to allow SBCL
reasonable opportunity to review and comment on the roll out plan prior to
implementation, and shall use its good faith efforts to incorporate SBCL's
comments thereon. Such roll out, however, shall not be made to any Provider
which has not executed an agreement containing the provisions set forth in
EXHIBIT II.B.2(a) or (b).
5. CUSTOMER SUPPORT. ActaMed will provide all reasonably
necessary and appropriate end user support for issues relating to connectivity
to the Network utilizing any Network Software in use at such time, including
without limitation, help desk assistance to Automated Providers, hardware
support to applicable Automated Providers, user training and bug fixes to the
Network. All customer support services shall be performed in a competent and
professional manner meeting or exceeding generally accepted industry standards
for confidential EDI and will be rendered by qualified personnel who will
perform the tasks assigned consistently with good professional practice and the
state of the art involved. SBCL shall have the right to request the removal
from Automated Providers accounts of any ActaMed personnel used by ActaMed to
perform customer support services, provided such objection would not constitute
unlawful discrimination, if SBCL becomes aware that such person is causing
customer dissatisfaction. If an objection is raised by SBCL, ActaMed agrees to
confer with SBCL and endeavor to furnish a replacement as quickly as is
practicable.
6. MONITORING. ActaMed shall continuously monitor its
performance against the Performance Standards and shall notify SBCL at any time
when it fails to meet the Performance Standards. SBCL shall similarly notify
ActaMed of any such failure, provided that the failure to notify shall not
constitute a waiver of SBCL's rights hereunder. In the event that ActaMed fails
to meet any Performance Standard at any time, ActaMed shall promptly diagnose
the cause of the failure and shall work continuously and diligently to correct
such failure to perform until it is corrected. Any failure to meet the
Performance Standards which occurs while ActaMed is working to remedy the
problem shall continue to be counted for the purposes of Section XII.B.1,
Section VII.B.4 and IV.F.
7. REPORTS. ActaMed and SBCL will, at their own expense, provide
the other with the reports specified on EXHIBIT III.B.7 hereto at the times
specified thereon.
C. PERFORMANCE STANDARDS. "Performance Standards" shall mean the
Network Standards and the Customer Support Standards. EXHIBIT III.C-1 to this
Agreement specifies the performance standards for the Network which must be
maintained and the applicable time periods for measuring compliance with such
standards (the "NETWORK STANDARDS"). EXHIBIT III.C-2 to this Agreement
specifies the customer support standards ActaMed must achieve and maintain and
the applicable time periods for measuring compliance with such standards (the
"CUSTOMER SUPPORT STANDARDS"). In no event shall the Performance Standards be
less than the comparable Network maintenance and support standards and services
ActaMed utilizes for or provides to its other customers receiving services
comparable to Lab EDI Services. ActaMed shall have sixty (60) days following
the date
-8-
<PAGE>
hereof to validate the metric performance level set forth in the Performance
Standards as representative of SBCL's provision of services which are now
Agreed Services. ActaMed shall perform the validation (with cooperation from
and access to relevant records and data of SBCL) within such sixty (60) day
period, and based upon the period of [*]. In the event that ActaMed's
validation process yields a metric different from that set forth in the
Performance Standards, a new metric for this Agreement shall be mutually
agreed by SBCL and ActaMed, with any disputes with respect thereto resolved
in accordance with Section XV hereof.
D. SBCL OBLIGATIONS. SBCL shall have no obligation to provide any
support, training or maintenance services to Automated Providers, other than as
expressly set forth herein.
E. Records and Audits.
1. ActaMed shall maintain accurate and complete records
regarding the transmissions to and from Automated Providers and SBCL in
accordance with accepted information storage practices in the clinical
laboratories industry and in compliance with applicable Regulations, but in
no event for less than [*] or such longer period as may be required by
Regulations or the Integrity Agreement.
2. The records maintained pursuant to Section III.E.1 above shall
include without limitation records of the amounts ActaMed charges SBCL under
this Agreement, with a system of audit trails, records and controls sufficient
to allow SBCL to audit such transactions and charges under this Agreement and to
assure satisfaction of any requirements imposed on SBCL by their external
auditors or on ActaMed or SBCL by government officials enforcing applicable
Regulations.
3. In addition to the grant of Audit Rights pursuant to Sections
IV.B, IV.C.3 and VI.B of this Agreement, SBCL shall have the right, exercisable
not more often than twice in each calendar year for the first three years after
the date hereof, and once in each calendar year thereafter, to have any of its
agents or employees, who or which are reasonably acceptable to ActaMed, audit,
in accordance with the Audit Rights, the books and records of ActaMed relating
to such SBCL transactions to examine or determine the proper amounts which
should have been billed to SBCL, the amounts which were billed to SBCL, and the
amounts which SBCL has paid under this Agreement.
4. In any exercise of Audit Rights hereunder, including without
limitation pursuant to Section III.E.3, SBCL shall give ActaMed two week's
prior notice of any such audit, and shall abide by reasonable ActaMed
security and confidentiality procedures during the audit. SBCL and ActaMed
shall each bear their own costs associated with such audit, provided that in
the event the audit determines that ActaMed has overcharged SBCL by more than
ten percent (10%) of the amount properly due ActaMed in any month, ActaMed
shall pay all costs of such audit. If the audit reveals an overpayment by
SBCL to ActaMed, ActaMed shall promptly refund such overpayment to
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-9-
<PAGE>
SBCL. If the audit reveals an underpayment by SBCL, SBCL shall promptly pay
to ActaMed the amount of such underpayment.
IV. PAYMENTS TO ACTAMED BY SBCL.
A. FEES FOR FIXED FEE SITES. SBCL will pay ActaMed for the Agreed
Services rendered to Fixed Fee Sites as follows:
1. Fixed Fee payments shall be due [*] on the first (1st)
business day of [*] beginning on January 2, 1998 and shall be in an amount
equal to
a. from January 2, 1998 until the day before the first
business day of [*], [*] per month;
b. from the first business day of [*] until [*].
B. TRANSACTION FEE FOR SITES OTHER THAN FIXED FEE SITES. From the
Region One Transfer Date and continuing until the day before the [*] SBCL
will pay to ActaMed, for Agreed Services in respect of sites which are not
Fixed Fee Sites only, within thirty (30) days after receipt of an invoice
from ActaMed detailing the charges then due, a fee equal to the sum of [*]
SBCL in accordance with the Performance Standards during the period covered
by the invoice (the "TRANSACTION FEE").
C. [*]. Provided the conditions set forth in Section IV.D are
satisfied, SBCL shall pay the following amounts to ActaMed as hereinafter in
this Section IV.C provided:
1. An amount (the "FIRST VARIABLE FEE") equal to (i) [*] minus
the aggregate of the amount billed to SBCL pursuant to Section IV.B.1 above
(the "TRANSACTION FEE AMOUNT") prior to the [*]; (ii) [*] minus the sum of
(A) the Transaction Fee Amount for the period from the date hereof to the [*]
and (B) the amount paid pursuant to clause (i) above; and (iii) [*] minus the
sum of (A) the Transaction Fee Amount for the period from the date hereof to
the [*] and (B) the amount paid pursuant to clauses (i) and (ii) above.
2. An amount (the "SECOND VARIABLE FEE" and together with the
First Variable Fee, the "VARIABLE FEES") equal to (i) [*] minus the aggregate
of the amount paid plus amounts owed (whether or not billed) pursuant to
Section IV.M.1 below (the "PIF AMOUNT") prior to the [*]; (ii) [*] minus the
sum of (A) the PIF Amount for the period from the date hereof to the
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-10-
<PAGE>
[*] and (B) the amount paid pursuant to clause (i) above; and (iii) [*] minus
the sum of (A) the PIF Amount for the period from the date hereof to the [*]
and (B) the amount paid pursuant to clauses (i) and (ii) above; PROVIDED THAT
if the PIF Amount with respect to an annual period (other than the last such
annual period) is at least [*] of the aforementioned dollar amount for that
annual period, no payment shall be due under this Section IV.B.2 for such
annual period.
3. Subject to Section IV.D, the Variable Fees shall be paid
annually within thirty (30) days after invoice therefor from ActaMed, which
shall be (i) submitted to SBCL within [*] (ii) detail the calculation
thereof, and (iii) reflect the Variable Fees payable in respect of the most
recently completed annual period only. SBCL shall have Audit Rights with
respect to any disputed amount of the Variable Fees.
D. CONDITIONS TO [*]. ActaMed and SBCL have agreed that the
foregoing [*] with respect to the provision of Lab EDI Services after the
date hereof shall apply (i) [*] and (ii) to the extent set forth in this
Section IV.D:
1. With respect to [*] (i) such fees shall cease to be payable
if (i) ActaMed shall fail to satisfy any of the Key Performance Standards, or
(ii) such fees [*] for the applicable year shall not be payable (but shall be
treated as paid for purposes of calculation of any amount payable in the
following year) if any of the following shall occur:
a. As of [*] shall [*] of [*] at [*] it has [*] as of [*];
b. As of [*] shall [*] of [*] at [*] it has [*] as of [*];
c. As of [*] shall [*] of [*] at [*] it has [*] as of [*];
2. With respect to the [*] such fees shall be payable [*] in
accordance with the Performance Standards [*] pursuant to Section [*].
E. LATE FEE. A late fee of [*] per month on the unpaid balance of
any payments owing pursuant to this Section IV after expiration of the thirty
(30) day period for payment thereof shall be due from SBCL.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-11-
<PAGE>
F. [*] OF PAYMENTS. After the [*] Anniversary, with respect to any
month after ActaMed has [*] with the [*] for [*] SBCL may, at its option, [*]
or other [*] to [*] for such month [*] established with [*] to be [*] the
date as of which [*] with the [*].
G. DEFINITION OF FIXED FEE SITES. "Fixed Fee Sites" shall mean the
[*] PROVIDED HOWEVER THAT:
1. if the number of SBCL Sites transferred to ActaMed on any
Transfer Date, when added to the number of ActaMed Sites on the date of such
Transfer, totals more than [*] any sites in excess of [*] (such excess to be
identified as described in the next sentence) shall not be Fixed Fee Sites.
The sites to be excluded from Fixed Fee Sites will be (i) from the Region
transferred on such Transfer Date, and (ii) selected, in order, from a list
of such sites that is sorted on the basis of the date of the first successful
Requisition from each site, beginning with the site which had the most recent
first successful Requisition, and continuing to the sites with the next most
recent first successful Requisition; and
2. if, on the last day of [*] the number of sites that are
Fixed Fee Sites [*] a number of sites, not to exceed [*] sites in any year,
that are not Fixed Fee Sites [*] PROVIDED THAT the aggregate number of Fixed
Fee Sites [*]. The [*] will be [*] in order, from a list of [*] that is
sorted on the basis of the date of the first successful Requisition from a
site, beginning with the site on such list which had the least recent first
successful Requisition, and continuing to the sites with next least recent
first successful Requisition; [*].
H. RENEGOTIATION OF PRICES. For a period of at least [*] prior to
[*] the parties will negotiate new Transaction Fees which shall apply for
the [*] period beginning on [*]. The parties will thereafter similarly
negotiate new Transaction Fees for each two (2) year period thereafter for
each renewal period in the term of this Agreement. [*]
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-12-
<PAGE>
[*].
I. EFFECT OF [*] CHANGES. If either of the following occurs, then
the parties agree to negotiate in good faith to restructure the Transaction
Fees payable or other provisions hereunder in a manner that will be fair to
both parties while at the same time preserving the economic expectations of
the parties under this Agreement to the greatest extent possible and in a
manner consistent with the [*]. Any dispute as to the amendments to this
Agreement to be made in the event of a [*] shall be settled in accordance
with the procedures set forth in Article XV hereof.
1. Any [*] is [*] or determined to [*] including without
limitation any significant reduction in SBCL's [*] or significant increase in
the [*] as compared to SBCL's [*] and [*] as of the date of this Agreement
as set forth on EXHIBIT IV.I hereto (which shall be delivered within thirty
(30) days after the date hereof); or
2. if the Automated Providers' [*] such that the effective [*]
for such period [*] with no corresponding [*].
J. PHONE LINE TRANSFER COSTS. SBCL shall reimburse ActaMed for [*]
of any charges, assessments, fees or other amounts incurred by ActaMed for
the transfer of any dedicated phone lines installed in Automated Providers'
offices for Lab EDI Services into the ActaMed name, including without
limitation any transfer fees or new installation fees.
K. ActaMed Obligations Regarding Hardware.
1. ActaMed shall reimburse SBCL for the cost of hardware
purchased by SBCL and located at SBCL Sites other than Fixed Fee Sites in a
Region to be transferred to ActaMed on a Transfer Date.
2. Subject to the limitations of Section III.L.2(b) hereof,
ActaMed and SBCL understand and agree that, [*] are to [*] for providing [*]
to Providers, there will be situations where [*] is [*] for ActaMed to
provide Lab EDI Services to certain Providers. ActaMed desires that the
number of such new sites be capped. SBCL and ActaMed have therefore agreed
that:
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-13-
<PAGE>
a. ActaMed shall provide [*], PC Systems for up to [*].
ActaMed may provide hardware for such [*] by either moving existing PC
Systems from a canceled Fixed Fee Site or by providing new PC Systems, as it
determines in its sole discretion.
b. In addition, ActaMed shall provide, prior to the [*]
Anniversary, [*] PC Systems for New Sites or [*] in excess of the [*].
Notwithstanding the above, this obligation shall be (a) limited to [*] PC
Systems prior to the [*] and (b) reduced by each PC System the cost of which
is reimbursed to SBCL subject to Section IV.K.1 above.
c. Any PC Systems in excess of those required to be provided
by ActaMed under (i) and (ii) above may be provided by SBCL to the Automated
Provider, subject only to the Automated Provider entering into a contract with,
and satisfactory to, SBCL for the use of such PC System.
L. SPECIAL FEE FOR USE OF SCAN DEVELOPMENTS. SBCL will pay ActaMed
a fee equal to [*], or [*] received by SBCL for [*] that use SCAN
Developments for Lab EDI Services over the SCAN Network and which [*].
M. SPECIAL FEES FOR NEW SITES. From the Region One Transfer Date
and continuing until the day before the [*], SBCL will pay to ActaMed, within
thirty (30) days after receipt of an invoice from ActaMed detailing the
charges then due, the following amounts:
1. a one time fee of [*] for [*] services at each PIF Site [*]
or "PIF"); and
2. up to the first [*] of any out-of-pocket cost required to be
incurred by ActaMed to provide the bar code label printer to be used for
orders to SBCL Labs at any New Site or any [*] during the period covered by
the invoice. ActaMed shall charge the Automated Provider [*] using the bar
code label printer for anything other than Lab EDI Services for the fair
market value of any such use. If an Automated Provider ceases to use Lab EDI
Services, SBCL may direct where the printer previously installed at such
Automated Provider will be next installed or ActaMed shall purchase, at its
cost and without reimbursement under this Section IV.M.2, a bar code label
printer for installation at another Automated Provider's location to be
determined by SBCL.
N. DISPUTED INVOICES. In the event SBCL disputes any amount shown due
on such invoice, SBCL shall send a Dispute Notice to ActaMed. In such event,
SBCL shall timely pay any undisputed amount to ActaMed and shall have Audit
Rights with respect to the portions of ActaMed's books and records that relate
to the subject of the dispute. In the event the parties are unable to resolve
the disputed matter, the matter shall be resolved in accordance with Section XV
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-14-
<PAGE>
hereof and application of any late fee to such disputed amount shall be
tolled until conclusion of such proceedings and then applied only to the
amount so determined to be due.
V. CHANGES AND DEVELOPMENT OF NEW FUNCTIONALITY.
A. MAINTENANCE. ActaMed shall provide such maintenance upgrades and
updates to the Network as set forth on EXHIBIT V.A and shall maintain and
enhance the Network so as to improve from time to time the speed, accuracy,
security and other features and functions available for Lab EDI Services.
ActaMed shall make available to Automated Providers all such modified, upgraded,
enhanced or improved services or software at no additional charge except as
permitted by this Agreement or applicable agreement with Automated Providers.
B. YEAR 2000 COMPLIANCE. ActaMed shall provide, without charge to
SBCL or to Automated Providers (unless the Automated Providers own the PC
Systems needing Year 2000 compliance), such maintenance and hardware upgrades
and updates to the Network (other than the SBCL gateway), or other software
relating (or which will relate) to Lab EDI Services as is necessary for all such
software and related hardware to include acceptable design and performance
specifications so that any or all such software will not abruptly end or provide
invalid or incorrect results due to issues related to Year 2000 compliance and
will otherwise be in compliance with the warranties set forth in EXHIBIT V.B
hereto. Year 2000 compliance requires that the design and performance
specifications of the hardware, software and/or other items include, without
limitation: date data century recognition, calculations that accommodate same
century and multi-century formulas and date values, and date data interface
values that reflect the century change at the year 2000. SBCL shall provide
specifications for Year 2000 compliance for SBCL systems in sufficient time to
allow ActaMed and SBCL to mutually agree on and ActaMed to complete such
modifications as are necessary to enable ActaMed to meet the requirements of
this Section V.B. SBCL will also provide reasonable cooperation and assistance
to ensure ActaMed's understanding of the requirements of this Section V.B.
Prior to any sale of PC Systems to any Automated Provider or potential Automated
Provider, ActaMed shall disclose to such Automated Provider any Year 2000
compliance problems of such PC System which are then known to ActaMed after
reasonable inquiry. A condition of any such sale shall be appropriate
arrangements for making the PC System to be sold Year 2000 compliant. In this
regard, the sales price shall reflect the fair market value of the services
required to make the PC System Year 2000 compliant.
C. REQUIRED CHANGES. ActaMed shall be required to develop and
implement, at its expense except to the extent hereinafter provided, as
promptly as practicable and in no event later than thirty (30) days prior to
the effective date of the applicable Regulatory Change, any Changes which (i)
ActaMed determines are required for the Network Software to remain in
compliance with all applicable Regulations, or (ii) SBCL requests in writing
to ActaMed for compliance with Regulations of the Network Software.
1. If SBCL reasonably determines that ActaMed cannot provide such
required work by thirty (30) days prior to a deadline imposed by governmental
authority, SBCL shall have the
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-15-
<PAGE>
right to contract with a third party for such work or to do such work itself.
In such event, SBCL shall be reimbursed therefor by ActaMed, except as
provided in Section V.C.3 below.
2. Upon reasonable advance written notice to ActaMed, SBCL may
request, and if it so requests ActaMed shall use its good faith efforts to
accommodate, prioritization of such Changes over any other software development
work performed by or on behalf of ActaMed.
3. In any event, upon reasonable advance notice to ActaMed, SBCL
shall be entitled to change the prioritization of required Changes from time to
time and to resolve conflicts between Changes demanding equal prioritization to
the extent necessary to deliver any such Change not less than thirty (30) days
prior to any government imposed deadlines or as promptly as practicable.
4. If ActaMed disputes that Changes requested by SBCL pursuant
to clause (ii) of Section V.C are required by Regulations, either ActaMed or
SBCL shall be entitled to cause the dispute to be resolved in accordance with
the procedures set forth in Section XV.B.1.a and XV.B.1.b thereof. If such
process is used and results in substantial agreement with either (i) ActaMed,
then [*] (including the cost of FTEs) in implementing such Changes, or (ii)
SBCL, [*]. If such process is not used or does not result in an agreement as
to whether or not such Change is required by Regulations, ActaMed and SBCL
shall mutually agree on an outside counsel familiar with issues of the nature
involved in the dispute and the opinion of such counsel shall be binding on
the parties hereto.
D. ACTAMED DEVELOPED NEW FUNCTIONALITY. When ActaMed develops new
functionality for the Network that ActaMed offers generally to its customers,
which is not included in a maintenance release that ActaMed offers generally
to its customers pursuant to Section V.A. above, ActaMed will offer such new
functionality to Automated Providers on the same basis [*] subject to SBCL's
right to accept or reject such new functionality.
E. Development Work Requested by SBCL.
1. SBCL at any time may request that ActaMed perform additional
development work and, subject to the terms of this Section V.E, shall pay
ActaMed for such work at no higher than the then industry standard rates for
similar services.
a. If SBCL requests in writing that ActaMed provide
additional development work for use exclusively by SBCL and, regardless of
whether ActaMed or a third party actually performs such development work,
ActaMed shall either (i) [*] in which case such work shall be a "Perpetual
Exclusive Development", or (ii) acting in good faith, [*] in which case such
work shall be a "Temporary Exclusive Development". With respect to Perpetual
Exclusive Developments, ActaMed will not use or license
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-16-
<PAGE>
the use of the Perpetual Exclusive Developments (without regard to whether
they constitute SCAN Developments or ActaLab Software) other than in support
of Lab EDI Services. With respect to Temporary Exclusive Developments,
ActaMed will not use or license the use of Temporary Exclusive Developments
(without regard to whether they constitute SCAN Developments or ActaLab
Software) other than in support of Lab EDI Services for a period of [*] from
the date on which ActaMed first makes available to SBCL such Temporary
Exclusive Development for use on a commercial basis in support of SBCL's
laboratory testing services. After expiration of such [*] period, subject to
resolution of any dispute relating to ActaMed's initial designation of such
development work as a Temporary Exclusive Development pursuant to Section
V.E.1.b, such Temporary Exclusive Development shall no longer be an
Exclusive Development.
For purposes of this Section V.E, Perpetual Exclusive
Developments and Temporary Exclusive Developments shall include any Changes made
pursuant to Section V.C and paid for by SBCL by reason of Section V.C.4, to be
designated as Perpetual Exclusive Developments or Temporary Exclusive
Developments in accordance with the procedures set forth in this Section
V.E.1.a. All such developments are herein referred to collectively as
"Exclusive Developments."
b. Within twenty (20) days after receiving SBCL's request
pursuant to Section V.E.1.a, ActaMed shall notify SBCL of ActaMed's prices and
terms for performing such development work, and whether such work will
constitute a Perpetual Exclusive Development or a Temporary Exclusive
Development. If SBCL provides notice ("Acceptance Notice") accepting ActaMed's
price and performance terms, ActaMed shall perform such work at the accepted
price and on the accepted performance terms. If SBCL provides notice that it
disputes ActaMed's determination that the development work should constitute a
Temporary Exclusive Development, the parties shall resolve the dispute in
accordance with Section XV. If either (i) ActaMed declines any work requested
pursuant to this Section V.E.1, or (ii) SBCL provides notice that it does not
accept ActaMed's price and performance terms, then SBCL may engage a third party
to perform such work.
c. Any contract between ActaMed and SBCL (or a third party
developer and SBCL) for development of Exclusive Developments shall allocate
ownership of and other rights with respect to the Exclusive Developments as
between ActaMed and SBCL, in the manner contemplated by the License Agreement
and Development Agreement, including, without limitation, Sections 2.1.4 and
2.3.2 of the License Agreement.
2. If, at any time, SBCL chooses to contract with ActaMed for a
dedicated services team from ActaMed to handle development of Changes to the
Network, the Licensed Materials, or SBCL's proprietary systems which are not
required to be performed by ActaMed pursuant to Section V.C and which are not
requested pursuant to Section V.E, ActaMed may elect whether to provide the
dedicated team and, if it so elects, shall do so only on terms and conditions
agreed to in advance by SBCL.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-17-
<PAGE>
F. Development Work Requested or Used by Another ActaMed Customer.
1. When ActaMed performs development work on the Network at the
request of another ActaMed customer, SBCL shall have the right to obtain [*]
but only for so long as ActaMed has the legal right to [*] to SBCL and [*] is
not proprietary to the contracting party.
2. When ActaMed performs development work on the Network at the
request of SBCL and such work is usable in connectivity with Other Labs (and is
not an Exclusive Development), [*].
G. ACCESS AND COOPERATION. Whenever SBCL shall use a third party
developer, ActaMed shall allow such third party such access to the Network as
shall be reasonably necessary to complete such work and shall cooperate with
such third party, PROVIDED THAT such access and cooperation shall be subject
to such third party (i) executing reasonable and appropriate security and
confidentiality agreements with ActaMed, (ii) abiding by ActaMed's internal
policies applicable to all third party developers, and (iii) agreeing to [*]
in providing such access and cooperation.
H. EMPLOYEE WAIVERS. ActaMed shall ensure that all employees or
agents who perform customer support services or have access to any Network
Software (whether in preliminary or final form) have signed non-disclosure and
assignment agreements that, at minimum, contain provisions (i) prohibiting the
disclosure of Confidential Information to the same extent as is set forth in
Section X hereof, and (ii) effecting the complete transfer and assignment
(without further consideration) by such employee or agent to SBCL or ActaMed, as
appropriate, of all right, title and interest to all software and documentation
and any proprietary rights thereto to the extent required pursuant to the
License Agreement.
I. STATEMENT OF WORK AND ACCEPTANCE FOR NEW WORK. In the event any
Change projected to cost in excess of [*] is to be made by ActaMed pursuant
to this Section V, ActaMed shall deliver a Statement of Work therefor within
thirty (30) days after the Change becomes known to it and shall, subject to
the other provisions of this Section V, dedicate sufficient resources to the
development and implementation of such Change as shall be necessary to gain
acceptance of and deploy the Change in accordance with such Statement of Work.
VI. COMPLIANCE MATTERS.
ActaMed is a computer technology company which provides electronic
connectivity services, and is not a health care provider. ActaMed acknowledges
that, for a laboratory services provider such as SBCL, the ability to assure
that it complies with applicable laws, rules or regulations ("Applicable Laws"),
including, but not limited to, the federal Physician Self-Referral Law, 42
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-18-
<PAGE>
U.S.C. 1395nn, and the regulations promulgated thereunder (together, the "Stark
Law"), similar state physician self-referral laws and regulations (together with
the Stark Law, the "Self-Referral Laws"), the federal Medicare/Medicaid
Antikickback Law and regulations promulgated thereunder (the "Federal
Antikickback Law"), and similar state antikickback laws and regulations
(together with the Federal Antikickback Law, the "Antikickback Laws"), is of
critical importance. SBCL and ActaMed intend that the outsourcing of the Lab
EDI Services to ActaMed and the subsequent provision of the Agreed Services by
ActaMed to SBCL be done in a manner that allows SBCL to maintain its compliance
with Applicable Laws. Accordingly, SBCL and ActaMed have agreed to the
provisions set forth in this Section VI, although SBCL and ActaMed understand
and agree that the provisions of this Section VI and of the separate SOPs (as
defined below) that may be agreed to from time to time by SBCL and ActaMed may
not be necessary or may be more restrictive than necessary to assure SBCL's
continued compliance with Applicable Laws.
A. Representation, Warranty and Covenant. ActaMed represents,
warrants, and covenants to SBCL as follows:
1. ActaMed will not directly or indirectly provide any
remuneration, as defined in the applicable Self-Referral Laws or Antikickback
Laws, to any Provider to whom any of such Self-Referral Laws or Antikickback
Laws applies on behalf of SBCL, except for direct or indirect remuneration
permitted by such law.
2. In furtherance and not in limitation of the foregoing, SBCL
and ActaMed may, from time to time, agree upon certain principles, activities,
agreements, standard operating procedures and/or actions (the "SOPs") that one
or both parties, as applicable, will follow or undertake to help SBCL assure its
compliance with Applicable Laws, and each party will follow any such SOPs
applicable to it in the course of conducting its respective business.
3. With respect to [*] to which ActaMed is [*] in connection
with the provision of Lab EDI Services, ActaMed will not [*] [*] unless and
until SBCL has informed ActaMed in writing that it is willing to [*] and that
ActaMed and SBCL have agreed upon [*].
4. ActaMed will provide any reasonable assistance that SBCL may
request from ActaMed, including the provision of information or other
assistance, in order for SBCL to fulfill any obligation that SBCL, in its sole
discretion, determines it has under the Integrity Agreement. Notwithstanding
the foregoing, nothing in this provision is intended to or should be interpreted
to mean that ActaMed is subject to any of the provisions of the Integrity
Agreement.
5. In the event that SBCL becomes aware of an issue with respect
to compliance with this Section VI, SBCL will promptly inform ActaMed of such
issue and ActaMed will promptly address such issue and take action to remedy any
such issue to the reasonable satisfaction of SBCL.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-19-
<PAGE>
6. ActaMed will notify SBCL of any proposed changes in ActaMed's
business practices with respect to EDI or the provision of LAB EDI Services
that are likely to affect SBCL or Automated Providers (other than [*]) a
reasonable period prior to the proposed implementation of such change or
changes and will provide SBCL with a reasonable opportunity to review those
proposed changes for compliance with this Section VI prior to implementation.
If [*] any such [*] based on an [*] or the [*], [*] with [*] to [*] before [*].
B. AUDIT RIGHTS. SBCL shall have Audit Rights, exercisable [*]
with respect to all of ActaMed's books, records and other materials that
relate to any compliance issues covered by this Section VI in order for SBCL
to determine ActaMed's fulfillment of its obligations hereunder or under any
separately agreed upon SOPs. When ActaMed enters into agreements with
Providers, it will use its best efforts to secure the right for ActaMed and,
if such Provider is an SBCL client, for SBCL, to audit such Provider's books
and records, and other materials and/or to inspect the Provider's premises to
assure that any compliance requirements established with such Provider are
being satisfied, and, upon request from SBCL, ActaMed will permit SBCL to
exercise such rights. In any exercise of Audit Rights under this Section
VI.B, SBCL shall give ActaMed two (2) weeks' prior written notice of any such
audit, and shall abide by reasonable ActaMed security and confidentiality
procedures during the audit. SBCL and ActaMed shall each bear their own
expenses associated with such audit.
C. DISPUTE RESOLUTION. Notwithstanding any other provision of this
Agreement to the contrary, because of the critical nature of compliance to
SBCL's business, disputes regarding compliance with this Section VI may not be
susceptible to resolution following normal dispute resolution mechanisms. In
the event that SBCL and ActaMed have a disagreement or dispute regarding
compliance with this Section VI, ActaMed agrees to use its best efforts in
working with SBCL to attempt to resolve that dispute as soon as possible. If
the parties are not able promptly to resolve any such dispute, and the parties
are not able to agree upon another mechanism, such as that provided for in
Section V.C.4 hereof, to resolve the issue, SBCL shall have the right to
exercise any and all remedies available to it under this Agreement, including
the right to terminate the Agreement.
VII. PREFERRED LAB EDI VENDOR.
A. PREFERRED LAB EDI VENDOR RELATIONSHIP. Provided none of the
events has occurred which is described in Section VII.B hereof, SBCL will, [*]
afford ActaMed "preferred Lab EDI Vendor" status in the United States to
the extent set forth in this Section VII. In this regard, SBCL will:
1. instruct its salespeople that when occasions arise where it is
appropriate to do so, inform Providers interested in Lab EDI Services that
ActaMed is its preferred vendor for all Lab EDI Services;
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-20-
<PAGE>
2. indicate that ActaMed is SBCL's preferred vendor for Lab EDI
Services in appropriate communications, whether internal or external, written or
oral, as determined by SBCL that relate to the topic of Lab EDI Services and
where a Lab EDI Services vendor is mentioned;
3. from the date when the ActaLab Software is approved by SBCL
for use by Automated Providers, (i) cause the marketing materials for SCAN
Software to be revised to feature the ActaLab Software; and (ii) train the SBCL
salespeople at no direct expense to ActaMed regarding the general features and
benefits of the ActaLab Software;
4. instruct its salespeople of the benefits to SBCL of ActaMed's
preferred status so that whenever they undertake sales efforts or negotiations
with a Provider whom SBCL believes to be a significant future customer for Lab
EDI Services with an SBCL Lab, or with a significant Automated Provider serviced
by ActaMed, insofar as it is known to the salesperson, for renewal or extension
of lab testing services at an SBCL Lab, if appropriate, invite representatives
from ActaMed to be included in such sales efforts and negotiations, so that
ActaMed may promote the use of the ActaLab Software to such customer;
5. inform appropriate third parties, including but not limited to
practice management system companies, electronic medical record vendors and
other EDI clearinghouses interested in establishing Lab EDI Services (or
services relating thereto) with SBCL, that, ActaMed is SBCL's preferred provider
for Lab EDI Services, and suggest that, provided ActaMed has the capabilities
sought by the third party, the third party pursue a contractual relationship
with ActaMed regarding such Lab EDI Services.
B. LIMITATIONS ON PREFERRED PROVIDER STATUS. The provisions of
Section VII.A shall apply unless and until any of the following occurs:
1. ActaMed ceases to offer products and services which have
features and functionality which are substantially comparable to other similar
products and services of similar vendors for services in the nature of Lab EDI
Services; SBCL provides written notice of same and, within thirty (30) days
after such notice is given, ActaMed fails to demonstrate to SBCL's reasonable
satisfaction that such determination is not accurate.
2. An Other Lab becomes a shareholder of ActaMed; provided that,
after ActaMed has consummated a Qualified Public Offering (as defined in
ActaMed's Fourth Amended and Restated Articles of Incorporation), this clause 2
shall apply only if the Other Lab becomes a shareholder of ActaMed by reason of
either an issuance of equity to the Other Lab by ActaMed or waiver of
restrictions in agreements between ActaMed and its stockholders which are
comparable to the Standstill Agreement between ActaMed and SBCL dated the date
hereof.
3. Any of the events described in clauses 2 through 5 of Section
XII.B shall have occurred (without regard to grace periods otherwise applicable
thereto and other than an event under clause 7 thereof which is based upon a
failure of SBCL to pay amounts due from it hereunder).
-21-
<PAGE>
4. ActaMed fails to meet any of the Performance Standards in [*]
or [*].
5. Any of the events described in Article X of the Assets
Purchase Agreement shall have occurred.
6. In the event that SBCL merges with or into, or acquires or
is acquired by an entity, owning or operating a clinical laboratory, or sells
substantially all of its assets to another entity in a transaction in which
this Agreement is assigned to such entity, SBCL shall have the right to elect
to have the preferred provider status removed with respect to such other
entity, PROVIDED THAT the [*] set forth in Section IV.C and D hereof shall
remain in effect after such transaction; and PROVIDED FURTHER THAT before
exercising such right, SBCL shall have used its good faith efforts to
preserve the original intention of the parties hereto.
C. EXCLUSIONS. Notwithstanding anything to the contrary contained
in this Agreement, including without limitation this Section VII, SBCL shall
be entitled without restriction and in its sole discretion, to (i) utilize or
change any EDI system for purposes of connectivity between an SBCL Lab and a
Provider [*], or between SBCL Labs, utilizing Lab EDI Services that SBCL has
already established or begun to establish connectivity capabilities as of the
date hereof, including without limitation those set forth on EXHIBIT VII.C-1
which Exhibit shall be delivered by January 15, 1998 and shall represent
SBCL's best efforts to identify all such capabilities which are significant
to SBCL; (ii) terminate or not renew its current contracts or arrangements
with third parties relating to Lab EDI Services; (iii) pursue future
arrangements or relationships for Lab EDI for any exclusion described in
EXHIBIT VII.C-2, and (iv) utilize or change any EDI system between SBCL Labs
and other facilities owned, managed and/or operated by SBCL.
D. EXCLUSIONS FOR [*]. Notwithstanding anything to the contrary
contained in this Agreement, including without limitation this Section VII,
SBCL shall be entitled without restriction and in its sole discretion, to
change, continue to use or install [*]. At some time in the future, SBCL will
consider a proposal from ActaMed for some or all of these [*] transactions
and enter into reasonable negotiations, if appropriate. For a period of [*]
from the date hereof, SBCL will not [*] Lab EDI Services without notifying
ActaMed and affording ActaMed opportunity to propose to provide such services.
E. FUTURE ACTAMED PARTICIPATION IN EXCLUDED ARRANGEMENTS.
Notwithstanding Section VII.C above, SBCL will endeavor to include ActaMed in
opportunities relating to the arrangements identified in Section VII.C(iii)
to the extent feasible and appropriate as determined by SBCL for Lab EDI or
physician connectivity. The nature and pricing of ActaMed's involvement will
be negotiated on a case by case basis.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-22-
<PAGE>
F. ELIGIBILITY AND CLAIMS PROCESSING SERVICES. During the initial
term of this Agreement, SBCL will use all reasonable business efforts,
consistent with its competitive needs in the lab testing business, to utilize
ActaMed as SBCL's preferred provider of electronic eligibility verification
and claims processing services to provide connectivity with all third party
payers with which SBCL desires connectivity and ActaMed is then connected,
PROVIDED THAT this Section VII.F shall apply only if (i) SBCL desires to use
an outside vendor for such services, and (ii) the prices proposed to be
charged by ActaMed for such services are [*]. In furtherance of such "preferred"
status, SBCL shall offer ActaMed as one of the potential providers of such
services in any written response to a request for proposals for lab testing
services. For each written SBCL proposal for the provision of such services,
SBCL shall provide ActaMed with a copy of the sections thereof describing
ActaMed's proposed services. SBCL shall provide ActaMed with such reasonable
opportunity as circumstances permit to review and correct or comment on any
such proposed language. Notwithstanding the foregoing, SBCL shall not be
obligated to comply with the provisions of this Section VII.F in those cases
in which (i) the payer designates (in the request for proposals or otherwise)
a provider of such services other than ActaMed, or (ii) it would violate any
Regulation, contractual provision or obligation by which SBCL is bound.
G. FURTHER EXCLUSIONS FOR NON-LABORATORY EDI. Nothing contained herein
shall prohibit SBCL from engaging in or contracting with third parties relating
to non laboratory related EDI transactions including but not limited to the
following, as long as each of the following is not intended primarily as a
connection from an Automated Provider to a network for the purposes of Lab EDI
Services (or services related thereto): [*].
VIII. COOPERATIVE RELATIONSHIP.
A. COOPERATION. Upon SBCL request, ActaMed will work with SBCL's
sales people to generate site connectivity and will use reasonable efforts to be
available to perform the technical portions of sales presentations made by
SBCL's sales people.
B. USE OF OTHER PARTIES' NAME. Each party shall have the right to
include the other party's name on its client or vendor list and to disclose the
nature of the services and products provided under this Agreement, so long as
such services and products are accurately represented; PROVIDED, HOWEVER, that
neither party has the right to use the other's name, trademarks or trade names
for other advertising, sales promotion, or publicity purposes without the
other's prior written consent.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-23-
<PAGE>
C. USER GROUP. ActaMed will establish a user group, to consult on
priorities and provide direction to ActaMed on system initiatives, which will
include representation from SBCL, Automated Providers and payers. At regular
intervals not less frequently than annually ActaMed will solicit user
suggestions, input and feedback regarding the Network.
D. ACTAMED'S OBLIGATION TO PROMOTE SB FOR DISEASE MANAGEMENT. For so
long as ActaMed is SBCL's preferred vendor pursuant to Section VII, ActaMed will
undertake actions similar to those set forth in Section VII.A to promote
SmithKline Beecham Corporation's Healthcare Services Division for the Disease
Management Business. "DISEASE MANAGEMENT BUSINESS" shall be defined in a
separate writing reasonably agreed upon by the parties within thirty (30) days
after the date hereof.
E. REFERENCE CHECKS. SBCL shall designate one or two individuals who
shall respond to a reasonable number of reference inquiries and visits (not to
exceed two visits in any calendar month) by customers and potential customers of
ActaMed on mutually agreeable terms. SBCL shall retain the right to refuse a
visit to any competitor or potential competitor of SBCL or to terminate the
visit of any customer or potential customer who does not abide by SBCL's
policies and procedures. ActaMed shall inform all customers and potential
customers allowed on SBCL's premises pursuant to this Section that they are
required to abide by SBCL's policies and procedures.
IX. SBCL'S OBLIGATIONS REGARDING THE NETWORK.
A. STANDARD FORMATS AND PROTOCOLS. SBCL shall receive and generate
transaction data and any other Lab EDI in a standard format and protocol
mutually agreed upon by the parties.
B. HARDWARE AND OPERATING ENVIRONMENT. SBCL shall provide, at its own
expense, all necessary hardware, including terminal equipment, compatible with
and suitable for its communications with the Network at the SBCL Labs. ActaMed
shall verify SBCL's operating environment with testing procedures implemented by
ActaMed from time to time, with advance notice to and approval from SBCL, which
approval shall not be unreasonably withheld or delayed.
C. NEW RELEASES OF SBCL PROPRIETARY SOFTWARE. SBCL will make
available to ActaMed all new releases and specifications for the SBCL gateway so
as to enable ActaMed to maintain the ActaMed Gateway substantially the same as
the SBCL gateway, including for Year 2000 compliance. In addition, SBCL will
give ActaMed advance notice of test code changes, new releases of SBCL
proprietary software and other SBCL host computer system changes (including host
computer systems operated by third party outsourcers on behalf of SBCL), if such
changes or releases will affect ActaMed's ability to transmit information over
the Network. If any changes are required to the Network by reason of such
actions by or on behalf of SBCL, the parties will mutually agree (consistent
with Section V hereof) in advance on the scope of the project, the deliverables,
deadlines, any fees ActaMed will charge SBCL, a test plan and an acceptance test
plan.
-24-
<PAGE>
X. CONFIDENTIALITY AND SECURITY.
A. DATA CONFIDENTIALITY. Each party agrees that patient clinical
records are Confidential Information and each party shall not disclose or
utilize individual lab test information in any way that would violate any
patient confidentiality obligation or any Regulations. Without limiting
ActaMed's obligations regarding Confidential Information which may be otherwise
provided for in this Agreement, ActaMed shall be responsible to ensure the
confidentiality of test results and patient information transmitted over the
Network, in accordance with all applicable Regulations governing such patient
confidential information, including to prevent anyone other than the sender and
addressee of Transmittal Information or their respective authorized employees
from monitoring, using, gaining access to or learning the import or contents of
any Transmittal Information.
B. DISTRIBUTION AND USE OF DATA. All Transmittal Information entered
onto the Network by SBCL or any Automated Provider from tests referred to SBCL,
shall be owned by SBCL and not by ActaMed. ActaMed shall not aggregate,
integrate, compile, regenerate, merge, manipulate or otherwise use the
Transmittal Information for any purposes and shall not provide the Transmittal
Information to any other person or entity, other than as specifically required
or allowed under the terms of this Agreement to perform the Agreed Services,
without the prior written consent of SBCL. ActaMed agrees that such information
cannot be aggregated for any Provider or among different customers' or other
health care providers or laboratory service providers for any purpose, without
SBCL's prior written consent.
1. If ActaMed is served with a warrant, subpoena or any other
order or request from a governmental body or any other entity or person for any
records or files of information transmitted over the Network, ActaMed will as
soon as practicable, and not in violation of law, deliver to SBCL a copy of such
warrant, subpoena, order or request and will not, without SBCL's prior written
consent, accede to the same unless and until required to do so under applicable
law.
2. ActaMed acknowledges and agrees that in the event it has
access to confidential data relating to an Automated Provider and/or the
Automated Providers's patients, employees and medical staffs, ActaMed will
hold such information in the strictest confidence and will not, without
SBCL's prior written consent, disclose any such information, including
without limitation in any regeneration, recompilation, or reorganization
thereof, or through any statistical analyses or provision of other excerpts
thereof. Without limiting the foregoing, ActaMed agrees that it shall limit
the ActaMed employees who have access to any patient identifiable health
information, including without limitation, laboratory test order or results
information, if any, to only those "need to know" employees of ActaMed as is
required to perform the Agreed Services to the level of the Performance
Standards set forth herein. Such employees shall be identified to SBCL in
advance of such access and shall have executed and delivered to ActaMed and
to SBCL, an agreement requiring non-disclosure of confidential information,
compliance with all ActaMed policies and procedures with respect to
Confidential Information and security of the Network (which shall be
consistent with the requirements in this Agreement), if applicable,
procedures established by SBCL and shall include an acknowledgment of
immediate termination for breach of such agreement. To the extent any
-25-
<PAGE>
employee of ActaMed acquires such access to patient health information through
any SBCL computer systems, or [*] ("SBCL ACCESS"), ActaMed shall cause such
employees to abide by SBCL's [*] Security Access procedures, and shall
deliver to SBCL such agreements reflecting same as may be required by SBCL and
identified to ActaMed in writing from time to time. ActaMed shall be
responsible for promptly notifying SBCL if any employee with SBCL Access is
terminated or leaves the employment of ActaMed.
3. Subject to the requirements of Section X.A, ActaMed may, at
[*] of [*] to such [*] for which the [*] from such [*] without the [*] SBCL.
There shall be [*] such [*].
4. Subject to Section X.A and without limiting the above
restrictions in this Section X.B, ActaMed [*] without the [*]. A copy of [*]
shall be provided to SBCL. ActaMed agrees that, if SBCL's consent is
obtained, [*] to Automated Providers shall be made available only in
accordance with all applicable patient confidentiality laws of the states [*]
the patient and SBCL Labs and ActaMed are located, and only [*] or [*]. SBCL
shall have Audit Rights with respect to any disputed amounts hereunder.
C. TRADE SECRET NONDISCLOSURE COVENANT. Without limiting the
foregoing, Trade Secrets and Confidential Information and all physical
embodiments thereof received by either party (the "RECEIVING PARTY") from the
other party (the "DISCLOSING PARTY") during the term of this Agreement,
including those received pursuant to the exercise of Audit Rights as described
in Section III.E hereof, are confidential to and are and will remain the sole
and exclusive property of the Disclosing Party. In furtherance of the
foregoing:
1. At all times, both during the term of this Agreement and
after its termination, the Receiving Party shall hold all Trade Secrets of
the Disclosing Party in confidence, and will not use, copy or disclose such
Trade Secrets, or any physical embodiment thereof, or cause any of such Trade
Secrets to lose their character as Trade Secrets. At all times during the
term of this Agreement and for a period of [*] following the termination of
this Agreement, (except where a longer period is required pursuant to this
Agreement or Regulations) the Receiving Party shall hold the Confidential
Information of the Disclosing Party in confidence, and will not use, copy or
disclose such Confidential Information, or any physical embodiments thereof,
or cause any of such Confidential Information to lose its character or cease
to qualify as Confidential Information.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-26-
<PAGE>
2. Trade Secrets and Confidential Information shall be maintained
under secure conditions by the Receiving Party, using reasonable security
measures and in any event (1) not less than the same security measures used by
the Receiving Party for the protection of its own Trade Secrets and Confidential
Information of a similar kind, and (2) any specific security measures required
by this Agreement. The Receiving Party shall not remove, obscure or deface any
proprietary legend relating to the Disclosing Party's rights, on or from any
tangible embodiment of any Licensed Materials without the Disclosing Party's
prior written consent. Within thirty (30) days after termination of this
Agreement, the Receiving Party shall deliver to the Disclosing Party all Trade
Secrets and Confidential Information, and all physical embodiments thereof, then
in the custody, control or possession of the Receiving Party.
3. If the Receiving Party is ordered by a court, administrative
agency, or other governmental body of competent jurisdiction to disclose Trade
Secrets or Confidential Information, or if it is served with or otherwise
becomes aware of a motion or similar request that such an order be issued, then
the Receiving Party will not be liable to the Disclosing Party for disclosure of
Trade Secrets or Confidential Information required by such order if the
Receiving Party complies with the following requirements: (i) if an already
issued order calls for immediate disclosure, then the Receiving Party shall
immediately move for or otherwise request a stay of such order to permit the
Disclosing Party to take measures such as are described in clause (iii); (ii)
the Receiving Party shall immediately notify the Disclosing Party of the motion
or order by the most expeditious possible means; and (iii) the Receiving Party
shall join or agree to (or at a minimum shall not oppose) a motion or similar
request by the Disclosing Party for an order protecting the confidentiality of
the Trade Secrets and Confidential Information, including joining or agreeing to
(or non opposition to) a motion for leave to intervene by the Disclosing Party.
4. The Receiving Party shall immediately report to the Disclosing
Party any attempt by any person of which the Receiving Party has knowledge (i)
to use or disclose any portion of the Trade Secrets and Confidential Information
without authorization from the Disclosing Party, or (ii) to copy, reverse
assemble, reverse compile or otherwise reverse engineer any part of the Trade
Secrets or Confidential Information (except as permitted herein).
D. PERMITTED DISCLOSURES. Notwithstanding any provisions of this
Agreement to the contrary, SBCL may disclose to the OIG as part of the
disclosures SBCL makes under its Integrity Agreement the fact that SBCL and
ActaMed have entered into the transactions contemplated by the parties and any
information relating to such transaction or this Agreement which SBCL
determines, in good faith upon advice of counsel, is required or, in light of
SBCL's obligations under the Integrity Agreement, appropriate for SBCL to make,
or SBCL proposes to make in response to a request for such information from the
OIG, provided that ActaMed shall be given opportunity (which shall be reasonable
in light of all facts and circumstances) to review and comment upon the
information SBCL intends to include in any such submission. In the event that
any such disclosure that SBCL intends to make includes any information that
constitutes Confidential Information of ActaMed or Trade Secrets of ActaMed,
SBCL will provide reasonable (in light of all facts and circumstances, including
the time frame in which such disclosure is required to be made) assistance
-27-
<PAGE>
to ActaMed to take reasonable steps to assure that such Confidential
Information or Trade Secrets of ActaMed are maintained in confidence,
including, but not limited to, (i) requesting that the OIG treat such
information as trade secrets, confidential information or financial
information within the meaning of the Freedom of Information Act, 5 U.S.C.
Section 552(b)(4), (ii) requesting of the OIG that SBCL and ActaMed be given
prior notice of any proposed release of such information to persons or
entities outside of the OIG; (iii) requesting that the OIG otherwise assure
the confidentiality of the information provided by ActaMed as if such
information was confidential information of SBCL [*] and taking other
reasonable steps that may be requested by ActaMed and to which SBCL may, in
its sole discretion, agree to assure that the OIG honors its confidentiality
obligations in that section; (iv) where such information is to be provided in
response to a request by the OIG, take reasonable steps to narrow the request
for information from the OIG in an appropriate manner in order to limit the
amount of information, if any, that constitute Confidential Information or
Trade Secrets of ActaMed covered by such request; and (v) make reasonable
efforts to permit ActaMed with the concurrence of the OIG, to disclose such
information directly to the OIG provided that in any such case, ActaMed shall
give SBCL a timely opportunity to review, comment upon, and approve the
information ActaMed intends to include in such submission. The additional
safeguards described in subsections (i) through (v) above are designed to
help assure the confidentiality of Confidential Information and Trade Secrets
the disclosure of which would have a material adverse impact on ActaMed.
These additional provisions are not intended to interfere with SBCL's ability
to meet its disclosure obligations under the Integrity Agreement.
Each party shall promptly notify the other in the event it receives
an inquiry, investigation, or request for information from the OIG or other
governmental agency into the matters relating to the proposed transaction.
XI. RELATIONSHIP MANAGERS.
ActaMed will designate a representative responsible for the SBCL
account and who will have decision making authority for ActaMed (the "ACTAMED
RELATIONSHIP MANAGER"). [*] will be the initial Relationship Manager for
ActaMed. The ActaMed Relationship Manager will be a member of the Oversight
Committee and shall attend planning meetings with SBCL, keep SBCL updated on
national trends in EDI and Lab EDI, and consult with SBCL regarding ActaMed's
software and Network strategy.
SBCL will designate a representative responsible for SBCL's
relationship with ActaMed who will have decision making authority for SBCL
(the "SBCL RELATIONSHIP MANAGER"). [*] will be the initial Relationship
Manager for SBCL. The SBCL Relationship Manager will be a member of the
Oversight Committee and will coordinate SBCL's activities with ActaMed,
attend planning meetings with ActaMed, and keep ActaMed updated on technical
developments with respect to [*] and Lab EDI.
Each party will consult with the other before changing its
Relationship Manager.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-28-
<PAGE>
XII. TERM AND TERMINATION.
A. INITIAL TERM AND RENEWALS. This Agreement shall continue for five
(5) years from the Region One Transfer Date, unless earlier terminated as
provided herein. Unless written notice of termination is given by SBCL not less
than one hundred eighty (180) days, or by ActaMed not less than three hundred
sixty (360) days, prior to the end of the term (including any extension or
renewal of the term pursuant to this Section XII.A), the term of this Agreement
will be automatically extended for successive two (2) year periods.
B. TERMINATION. A party may cause a termination of all rights and
obligations of the parties hereunder, except as provided in this Section XII
hereof, as follows:
1. In the event that ActaMed fails to meet any of the Key
Performance Standards in any [*] during any period of [*] SBCL may terminate
this Agreement immediately by giving written notice of termination to ActaMed.
2. SBCL may terminate this Agreement immediately following a
breach by ActaMed of its covenants set forth in Section VI hereof by giving
written notice of termination to ActaMed.
3. Either party may terminate this Agreement if the other party
shall fail to pay any amount when due from it hereunder (disregarding for this
purpose any unpaid amount in dispute which dispute is being pursued with
diligence) within thirty (30) days after written notice of a failure to pay is
provided by the terminating party to the nonpaying party.
4. If one party breaches any material provision of this
Agreement, which breach is not described in Sections XII.B.1-3 above (and
which is not a breach of Performance Standards other than the Key Performance
Standards), the nonbreaching party may terminate this Agreement by giving [*]
written notice of termination to the breaching party. If such breach is (in
the reasonable estimation of the terminating party) capable of being cured
during such period and the other party acts diligently and continuously to
cure such breach, the termination shall be suspended during such time,
PROVIDED THAT such breach is actually cured prior to the end of such period;
AND PROVIDED FURTHER THAT during the period from and after the time an
ActaMed breach is discovered, SBCL may, at its election, pay all Fixed Fees,
Transaction Fees, Variable Fees, PIFs and other amounts otherwise due ActaMed
hereunder into an escrow account established with a nationally recognized
financial institution selected by SBCL, to be released to ActaMed upon the
later of the date within such [*] period when the breach is cured or the date
prior to exercise of the termination right provided in this Section XII.B.4
as of which ActaMed shall have been not in breach of this Agreement for at
least thirty (30) days. If ActaMed proves, to SBCL's reasonable
satisfaction, that such amounts are needed in order to cure the breach, SBCL
will release amounts to enable ActaMed to cure the breach, in which case such
released amounts will be used by ActaMed exclusively for purposes of curing
such breach.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-29-
<PAGE>
5. If one party becomes insolvent, files bankruptcy, or has an
involuntary bankruptcy case filed against it which is not dismissed within
ninety (90) days, the other party may terminate this Agreement immediately by
giving written notice of termination to the breaching party.
C. EFFECT OF EXPIRATION. All rights and obligations of the parties
hereunder shall cease upon the expiration of this Agreement except that (i) the
obligations of the parties pursuant to Section X (relating to confidentiality),
and (ii) the exclusive use rights of SBCL pursuant to Section V (relating to
development work) shall continue in full force and effect indefinitely. In
addition, the obligations of the parties pursuant to Section IV (relating to
compliance with Regulations) shall continue for so long as SBCL shall have Long
Term Access or Short Term Access.
D. EFFECT OF TERMINATION. All rights and obligations of the parties
hereunder shall cease upon the effective date of the termination of this
Agreement except that (i) the obligations of the parties pursuant to Section
X (relating to confidentiality), (ii) the exclusive use rights of SBCL
pursuant to Section V (relating to development work), and (iii) the
obligations of ActaMed pursuant to Section XII.E hereof (relating to
termination transition), shall continue in full force and effect
indefinitely. In addition, the obligations of the parties pursuant to
Section IV (relating to compliance with Regulations) shall continue for so
long as SBCL shall have Long Term Access or Short Term Access. In the event
that ActaMed has terminated this agreement for SBCL's failure to pay
undisputed amounts due under this Agreement, ActaMed will not be required to
perform services for SBCL or to allow SBCL access to or use of the Network
during the termination transition period unless SBCL pays ActaMed in advance
for such services and Network access. Upon termination of this Agreement,
any amount in escrow pursuant to Section IV.F or Section XII.B.4 hereof shall
be paid to the terminating party.
E. Transition Upon Termination.
1. If this Agreement terminates as a result of a notice of
non-renewal given by ActaMed pursuant to Section XII.A, ActaMed will provide
[*] or, at SBCL's option,
a. SBCL may have [*] so long as ActaMed provides [*] (but
not less than [*]), or
b. SBCL may require ActaMed [*] prior to the effective
date of such termination, and SBCL may exercise the right to [*] as granted
by the License Agreement.
2. If this Agreement terminates as a result of a notice of
non-renewal given by SBCL pursuant to Section XII.A, ActaMed will provide [*]
and SBCL will have [*].
3. If SBCL terminates this Agreement pursuant to Section XII.B,
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-30-
<PAGE>
a. ActaMed will provide [*],
b. SBCL may require ActaMed [*] within [*] after
SBCL's notice of termination,
c. SBCL may exercise the right to [*] as granted by the
License Agreement, and
d. until such time [*] by SBCL on a commercial basis, SBCL
shall have Long Term Access.
4. [*] shall mean that [*] from [*] who have [*] or a version
of [*]. For [*] SBCL will [*] on the date notice of termination is given.
ActaMed will [*] and SBCL will [*] is rendered. If SBCL [*] (subject to [*]
to those provided in Section [*] hereof), ActaMed will [*]. ActaMed will have
[*] and SBCL will [*].
5. [*] shall mean that ActaMed [*] the date of termination.
For [*] SBCL will [*] the date of Termination. ActaMed will [*] the date
the bill is rendered. If SBCL [*] (subject to [*] to those provided in
Section [*] hereof), ActaMed will [*]. ActaMed will have [*] and SBCL will
have [*].
6. [*] shall mean [*] that will only provide [*] and allows [*],
to provide [*] ActaLab Software at their sites.
F. TRANSITION UPON TERMINATION. ActaMed's [*] shall mean (i) if the
date of termination occurs [*] the transfer to SBCL of [*] requested by SBCL
to [*] SBCL at such time [*] and (ii) providing SBCL, as promptly as
practicable, with [*] used for [*] whether or not [*] to which ActaMed is
in a position to [*] the effective date of the termination and to [*] to the
transition. In furtherance of and in addition to the foregoing, upon
termination or expiration of this Agreement, the parties shall effect, and
shall cooperate with each other in effecting,
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-31-
<PAGE>
the orderly and reasonable removal of ActaMed as a provider of Lab
EDI Services to Automated Providers in the manner that is least disruptive to
Automated Providers and which allows connectivity between SBCL Labs and
Automated Providers to continue uninterrupted with SBCL or a separate vendor.
The parties shall jointly develop a removal plan which will provide a reasonable
level of support consistent with Section III hereof to transition SBCL off the
Network. Each party shall bear its own expenses in developing and implementing
the removal plan.
G. LICENSE AGREEMENT. To the extent any provisions of the License
Agreement depend for their interpretation or application upon provisions of this
Agreement, such provisions shall survive termination or expiration of this
Agreement but solely for purposes of the License Agreement.
XIII. NONSOLICITATION.
A. BY SBCL. Until the occurrence of any of the events described in
Sections XIII.B, SBCL will not, directly or indirectly, solicit any ActaMed Site
to use a clinical laboratory test ordering or results reporting product other
than one serviced or distributed by or otherwise affiliated with ActaMed.
B. EXCEPTIONS TO SBCL NONSOLICITATION. The restrictions set forth in
Section XIII.A shall not apply from and after the occurrence of the following:
1. Any of the events described in clauses 1 through 5 of Section
XII.B shall have occurred (without regard to notice or grace periods otherwise
applicable thereto and disregarding for this purpose any termination event
arising by reason of nonpayment by SBCL of any amount not in dispute).
2. Any of the events described in Article X of the Assets
Purchase Agreement shall have occurred.
3. Notice of nonrenewal of this Agreement is given by (i)
ActaMed pursuant to Section XII.A in which case Section XIII.A shall not
apply for the last [*] of the then remaining term hereof, or (ii) SBCL in
which case Section XIII.A shall not apply for the last [*] of the then
remaining term hereof.
C. Noncompetition by ActaMed.
1. [*] ActaMed shall not, either individually or through any
affiliate, employee, director, officer or consultant, directly or indirectly,
(i) [*], or (ii) compete with SBCL in the Disease Management Business. The
specific terms of such noncompetition shall be detailed in the separate
writing referred to in Section VIII.D to be delivered within thirty (30) days
after the date hereof.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-32-
<PAGE>
2. At any time prior to [*], ActaMed shall not [*] at the SBCL
Sites transferred to ActaMed pursuant to the Purchase Agreement, including
without limitation, to install or be instrumental in causing [*] to [*]
located at such sites which enables the [*], or otherwise provide [*] which
facilitate [*].
XIV. OBLIGATION TO INDEMNIFY.
A. ACTAMED INDEMNITY. Subject to Section XIV.C hereunder, ActaMed
agrees to indemnify and hold harmless each SBCL Indemnitee against and in
respect of (i) all Losses, asserted against, imposed upon or incurred by any
SBCL Indemnitee by reason of or resulting from any breach of any representation
or warranty or covenant of ActaMed contained in this Agreement, as well as from
any negligent act or omission of ActaMed; and (ii) any and all actions, suits,
claims, proceedings, investigations, demands, assessments, audits, fines,
judgments, costs and other expenses (including, without limitation, reasonable
legal fees and expenses) incident to any Loss or to the enforcement of this
Section XIV.A.
B. SBCL INDEMNITY. Subject to Section XIV.C hereunder, SBCL agrees to
indemnify and hold harmless each ActaMed Indemnitee against and in respect of
(i) all Losses, asserted against, imposed upon or incurred by any ActaMed
Indemnitee by reason of or resulting from any breach of any representation or
warranty or covenant of SBCL contained in this Agreement, as well as from any
negligent act or omission of SBCL; and (ii) any and all actions, suits, claims,
proceedings, investigations, demands, assessments, audits, fines, judgments,
costs and other expenses (including, without limitation, reasonable legal fees
and expenses) incident to any Loss or to the enforcement of this Section XIV.B.
C. ALLOCATION OF RISK.
1. ActaMed shall not be liable to SBCL (or to any person claiming
to have been injured by SBCL) for any lab testing error, billing error, or other
action or failure to act of SBCL, or any error or mistake not caused by ActaMed
and made by SBCL in the reporting of lab testing results to ActaMed for delivery
by the Network, and SBCL shall hold ActaMed harmless from all claims caused by
such errors or mistakes to the extent made by SBCL.
2. SBCL shall not be liable to ActaMed (or to any person claiming
to have been injured by ActaMed) for any error in Transmittal Information,
billing error, or other action or failure to act of ActaMed, or any error or
mistake not caused by SBCL and made by ActaMed in the transmission of test
orders and results over the Network, and ActaMed shall hold SBCL harmless from
all claims caused by such errors or mistakes to the extent made by ActaMed.
3. Neither party shall be liable to the other hereunder for
consequential, special, punitive or exemplary damages of any kind (including,
but not limited to, lost profits, loss of business or other similar damages)
arising out of any action or proceeding except and only to the
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-33-
<PAGE>
extent that such damages arise from or relate to (i) the failure of a party
to comply with Regulations as required by this Agreement, (ii) an action in
tort initiated by a third party against either or both of the parties hereto,
or (iii) breach of a party's confidentiality undertakings set forth herein.
4. Neither party shall be liable to the other hereunder in
connection with any action or proceeding arising from or relating to a matter
covered by this Section XIV, or for breach of this Agreement, for an amount
in excess of the greater of (i) [*] or (ii) the [*] prior to the date on
which such breach occurs; PROVIDED THAT this limitation shall not apply to
any Losses or other damages arising out of or relating to any action
described in clauses [*].
D. CLAIMS NOTICE. A Claim shall be made by any Indemnitee by delivery
of a Claims Notice to any Indemnifying Party requesting indemnification and
specifying the basis on which indemnification is sought and the amount of
asserted Losses and, in the case of a Third Party Claim, containing (by
attachment or otherwise) such other information as such Indemnitee shall have
concerning such Third Party Claim.
E. PROCEDURES INVOLVING NON THIRD PARTY CLAIMS. If the Claim involves
a matter other than a Third Party Claim, the Indemnifying Party shall raise any
objection to such Claim within a reasonable period of time by delivery of a
written notice of such objection to such Indemnitee specifying in reasonable
detail the basis for such objection. If an objection is timely interposed by
the Indemnifying Party, the Indemnifying Party and the Indemnitee shall
cooperate in the compromise of the Claim or resolve any disagreement in
accordance with Section XV hereof.
F. PROCEDURES INVOLVING THIRD PARTY CLAIMS. The obligations and
liabilities of the parties hereunder with respect to a Third Party Claim shall
be subject to the following terms and conditions:
1. The Indemnitee shall give the Indemnifying Party written
notice of a Third Party Claim promptly after receipt by the Indemnitee of notice
thereof, and the Indemnifying Party may undertake the defense, compromise and
settlement thereof by representatives of its own choosing reasonably acceptable
to the Indemnitee. The failure of the Indemnitee to notify the Indemnifying
Party of such claim shall not relieve the Indemnifying Party of any liability
that they may have with respect to such claim except to the extent the
Indemnifying Party demonstrates that the defense of such claim is prejudiced by
such failure. The assumption of the defense, compromise and settlement of any
such Third Party Claim by the Indemnifying Party shall be an acknowledgment of
the obligation of the Indemnifying Party to indemnify the Indemnitee with
respect to such claim hereunder. If the Indemnitee desires to participate in,
but not control, any such defense, compromise and settlement, it may do so at
its sole cost and expense. If, however, the Indemnifying Party fails or refuses
to undertake the defense of such Third Party Claim within ten (10) days after
written notice of such claim has been given to the Indemnifying Party by the
Indemnitee, the Indemnitee shall have the right to undertake the defense,
compromise and settlement
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-34-
<PAGE>
of such claim with counsel of its own choosing. In the circumstances
described in the preceding sentence, the Indemnitee shall, promptly upon its
assumption of the defense of such claim, make a Claim as specified in
Sections XIV.A and XIV.B which shall be deemed a Claim that is not a Third
Party Claim for the purposes of the procedures set forth herein.
2. If, in the reasonable opinion of the Indemnitee, any Third
Party Claim or the litigation or resolution thereof involves an issue or matter
which could have a material adverse effect on the business, operations, assets,
properties or prospects of the Indemnitee, the Indemnitee shall have the right
to control the defense, compromise and settlement of such Third Party Claim
undertaken by the Indemnifying Party, and the reasonable costs and expenses of
the Indemnitee in connection therewith shall be included as part of the
indemnification obligations of the Indemnifying Party hereunder. If the
Indemnitee shall elect to exercise such right, the Indemnifying Party shall have
the right to participate in, but not control, the defense, compromise and
settlement of such Third Party Claim at its sole cost and expense.
3. No settlement of a Third Party Claim involving the asserted
liability of the Indemnifying Party under this Article shall be made without the
prior written consent by or on behalf of the Indemnifying Party, which consent
shall not be unreasonably withheld or delayed. If the Indemnifying Party
assumes the defense of such a Third Party Claim, (1) no compromise or settlement
thereof may be effected by the Indemnifying Party without the Indemnitee's
consent unless (a) there is no finding or admission of any violation of law or
any violation of the rights of any person and no effect on any other claim that
may be made against the Indemnitee (b) the sole relief provided is monetary
damages that are paid in full by the Indemnifying Party and (c) the compromise
or settlement includes, as an unconditional term thereof, the giving by the
claimant or the plaintiff to the Indemnitee of a release, in form and substance
satisfactory to the Indemnitee, from all liability in respect of such Third
Party Claim, and (2) the Indemnitee shall have no liability with respect to any
compromise or settlement thereof effected without its consent.
G. NO RELEASE FOR FRAUD. Nothing contained in this Agreement shall
relieve or limit the liability of a party or any officer or director of such
party from any Liability arising out of or resulting from common law fraud or
intentional misrepresentation in connection with the transactions contemplated
by this Agreement or in connection with the delivery of this Agreement. Each
ActaMed Indemnitee or SBCL Indemnitee, as the case may be, shall have a right to
indemnification for any Loss incurred as the result of any common law fraud or
intentional misrepresentation by SBCL or ActaMed, respectively, or any officer
or director thereof.
H. Payment.
1. If any party is required to make any payment under this
Section XIV, such party shall promptly pay the Indemnified Party the amount so
determined. If there is a dispute as to the amount or manner of determination
of any indemnity obligation owed under this Section XIV, the Indemnifying Party
shall nevertheless pay when due such portion, if any, of the obligation as shall
not be subject to dispute. The difference, if any, between the amount of the
obligation
-35-
<PAGE>
ultimately determined as properly payable under this Section XIV and
the portion, if any, theretofore paid shall bear interest as set forth in
Section XIV.F.3.
2. Any items as to which an Indemnified Party is entitled to
payment under this Article may be paid by setoff against amounts payable to the
Indemnifying Party to the extent that such amounts are sufficient to pay such
items.
3. If all or part of any indemnification obligation under this
Agreement is not paid when due, then the Indemnifying Party shall pay the
Indemnified Party interest on the unpaid principal amount of the obligation from
the date the amount became due until payment in full, at the per annum rate of
interest announced from time to time by NationsBank South, N.A., to be its
"prime rate."
XV. DISPUTE RESOLUTION; ARBITRATION.
A. GENERAL. Except as otherwise provided in Section VI of this
Agreement, disputes between ActaMed and SBCL relating to the interpretation or
application of this provisions of this Agreement shall be resolved in accordance
with this Section XV.
B. INFORMAL DISPUTE RESOLUTION. Any dispute between the parties
arising out of or with respect to this Agreement, either with respect to the
interpretation of any provision of this Agreement or with respect to the
performance by ActaMed or SBCL, shall be resolved as provided in this Article.
1. Prior to the initiation of formal dispute resolution
procedures, the parties shall first attempt to resolve their dispute informally,
as follows:
a. The Representatives for each party shall meet for the
purpose of endeavoring to resolve such dispute. They shall meet as often as the
parties reasonably deem necessary in order to gather and furnish to the other
all information with respect to the matter in issue which the parties believe to
be appropriate and germane in connection with its resolution. The
Representatives shall discuss the problem and negotiate in good faith in an
effort to resolve the dispute without the necessity of any formal proceeding.
During the course of negotiations, all reasonable requests made by one party to
another for nonprivileged information, reasonably related to this Agreement,
shall be honored in order that each of the parties may be fully advised of the
other's position.
b. If, within fifteen (15) days after a matter has been
identified for resolution pursuant to this Section XV, either of the
Representatives concludes in good faith that amicable resolution through
continued negotiation in this forum does not appear likely, the matter will be
escalated by formal written notification to the SBCL President and the ActaMed
President. The parties will use their respective best efforts to cause the SBCL
President and the ActaMed President to meet to attempt to resolve the dispute.
-36-
<PAGE>
c. Formal proceedings for the resolution of a dispute may
not be commenced until the earlier of: (i) the date on which the SBCL President
and the ActaMed President conclude in good faith that amicable resolution
through continued negotiation of the matter does not appear likely; or (ii)
thirty (30) days after the dispute has been referred to the SBCL President and
the ActaMed President.
2. The provisions of this Section XV shall not be construed to
prevent a party from instituting, and a party is authorized to institute, formal
proceedings earlier to avoid the expiration of any applicable limitations
period.
C. ARBITRATION. If the parties are unable to resolve any controversy
arising under this Agreement as contemplated by Section XV.A and if such
controversy is not subject to Section XIV or Section XV.D, then such controversy
shall be submitted to mandatory and binding arbitration at the election of
either Party (the "DISPUTING PARTY") pursuant to the following conditions:
1. The Disputing Party shall notify the AAA and the other Party
in writing describing in reasonable detail the nature of the dispute (the
"DISPUTE NOTICE"). The parties shall each select a neutral arbitrator in
accordance with the rules of AAA and the two (2) arbitrators selected shall
select a third neutral arbitrator. The three (3) arbitrators so selected are
herein referred to as the "PANEL."
2. The Panel shall allow reasonable discovery as permitted by the
Federal Rules of Civil Procedure, to the extent consistent with the purpose of
the arbitration. The Panel shall have no power or authority to amend or
disregard any provision of this Section XV. The arbitration hearing shall be
commenced promptly and conducted expeditiously, with each of ActaMed and SBCL
being allocated one-half of the time for the presentation of its case. Unless
otherwise agreed to by the parties, an arbitration hearing shall be conducted on
consecutive days.
3. Should any arbitrator refuse or be unable to proceed with
arbitration proceedings as called for by this Section, such arbitrator shall be
replaced by an arbitrator selected in accordance with the rules of the AAA and
consistent with this Section XV.
4. The Panel rendering judgment upon disputes between parties as
provided in this Section XV shall, after reaching judgment and award, prepare
and distribute to the parties a writing describing the findings of fact and
conclusions of law relevant to such judgment and award and containing an opinion
setting forth the reasons for the giving or denial of any award. The award of
the arbitrator shall be final and binding on the parties, and judgment thereon
may be entered in a court of competent jurisdiction.
5. Arbitration hearings hereunder shall be held in Washington
D.C. or other mutually agreeable location.
6. The Panel shall be instructed that time is of the essence in
the arbitration proceeding. The Panel shall render its judgment or award within
fifteen (15) days following the
-37-
<PAGE>
conclusion of the hearing. Recognizing the express desire of the parties for
an expeditious means of dispute resolution, the arbitrator shall limit or
allow the parties to expand the scope of discovery as may be reasonable under
the circumstances.
D. LITIGATION. In the event of a breach of the confidentiality
obligations set forth in this Agreement, or in the event a party makes a good
faith determination that a breach of the terms of this Agreement by the other
party is such that the damages to such party resulting from the breach will be
so immediate, so large or severe, and so incapable of adequate redress after the
fact that a temporary restraining order or other immediate injunctive relief is
a necessary remedy, then such party may file a pleading with a court seeking
immediate injunctive relief. If a party files a pleading with a court seeking
immediate injunctive relief and this pleading is challenged by the other party
and the injunctive relief sought is not awarded in substantial part (or in the
event of a temporary restraining order is vacated upon challenge by the other
party), the party filing the pleading seeking immediate injunctive relief shall
pay all of the costs and attorneys' fees of the party successfully challenging
the pleading.
1. ActaMed and SBCL each consent to venue in Philadelphia,
Pennsylvania and to the nonexclusive jurisdiction of competent Pennsylvania
state courts or federal courts located in Philadelphia for all litigation which
may be brought, subject to the requirement for arbitration hereunder, with
respect to the terms of, and the transactions and relationships contemplated by,
this Agreement.
XVI. MISCELLANEOUS.
A. PUBLICITY. Each party hereto agrees that neither it, nor or any of
its representatives, shall make any public announcement with respect to this
Agreement or the transactions contemplated hereby without the prior consent of
the other party hereto unless required by law or judicial process, in which case
notification shall be given to the other party hereto prior to such disclosure
and the content of such disclosure approved by such other party, which approval
shall not be unreasonably withheld or delayed. Notwithstanding the foregoing,
ActaMed agrees that nothing in this Section XVI.A shall prohibit SBCL from
disclosing any information SBCL is permitted to disclose under Section X.D.
B. ENTIRE AGREEMENT. This Agreement, including the Exhibits to it,
constitutes the entire understanding between the parties and supersedes all
proposals, communications and agreements between the parties relating to its
subject matter. No amendment, change, or waiver of any provision of this
Agreement will be binding unless in writing and signed by both parties.
C. GOVERNING LAW. This Agreement will be governed by and construed in
accordance with the laws of the State of Georgia applicable to contracts made
and performed therein.
D. ASSIGNMENTS. Neither party may assign this Agreement without the
prior, written consent of the other party, which shall not be unreasonably
withheld; PROVIDED, HOWEVER, that SBCL may assign its rights and obligations
hereunder without approval of ActaMed to any of its affiliates,
-38-
<PAGE>
or an acquiror of substantially all of its assets; PROVIDED FURTHER that
ActaMed may assign its rights and obligations under this Agreement without
the approval of SBCL to any person that acquires all or substantially all of
the business or assets of ActaMed related to the ActaLab Software and the
Network, if such person (or any affiliate of such person) is not engaged in
the business of providing laboratory testing services. Any attempted
assignment without such consent shall be void. If the parties cannot agree
upon whether a company competes with SBCL for lab testing, the parties shall
resolve the dispute pursuant to Section XV. Any assignment with consent does
not release the assigning party from any of its obligations under this
Agreement unless the consent so states.
E. NOTICES. Any notices relating to this Agreement shall be in
writing and will be sent by certified United States mail, postage prepaid,
return receipt requested, or by facsimile transmission or overnight courier
service, addressed to the party at the address set forth below, or at such
different address as a party has advised to the other party in writing and shall
be deemed given and received when actually received:
If to SBCL:
SmithKline Beecham Clinical Laboratories, Inc.
1201 South Collegeville Road
Collegeville, Pennsylvania 19426
Attention: John B. Okkerse, Jr., Ph.D., President
Telephone: [*]
Telecopy: [*]
With a copy to:
SmithKline Beecham Corporation
One Franklin Plaza
16th and Race Streets
Philadelphia, PA 19103
Attention: General Counsel-U.S.
Telephone: [*]
Telecopy: [*]
If to ActaMed:
ActaMed Corporation
Suite 600
7000 Central Parkway
Atlanta, Georgia 30328
Attention: Chief Financial Officer
Telephone: (770)352-1600
Telecopy: (770)352-1815
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-39-
<PAGE>
with a copy to:
Alston & Bird
One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3424
Attention: John C. Weitnauer, Esquire
Telephone: (404) 881-7780
Telecopy Number: (404) 881-7777
F. SEVERABILITY. In the event one or more of the provisions of this
Agreement are found to be invalid, illegal or unenforceable by a court with
jurisdiction, the remaining provisions shall continue in full force and effect.
G. FORCE MAJEURE. The obligations of the parties under this Agreement
(other than the obligation to make payments) shall be suspended to the extent a
party is hindered or prevented from complying therewith because of labor
disturbances (including strikes or lockouts), war, acts of God, fires, storms,
accidents, governmental regulations, failure of vendors or suppliers or any
other cause whatsoever beyond a party's control. For so long as such
circumstances prevail, the party whose performance is delayed or hindered shall
continue to use all commercially reasonable efforts to recommence performance
without delay.
H. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
THIS AGREEMENT CONTAINS A BINDING ARBITRATION PROVISION THAT MAY BE
ENFORCED BY THE PARTIES.
-40-
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Services Agreement as
of the date set forth above.
ACTAMED CORPORATION
By: /s/
---------------------------------------
Its: President
--------------------------------------
SMITHKLINE BEECHAM CLINICAL LABORATORIES, INC.
By: /s/
---------------------------------------
Its: President
--------------------------------------
<PAGE>
EXHIBITS
<TABLE>
<S> <C>
Exhibit A -- Definitions-
Exhibit II.B.2(a) -- Automated Provider Contract Amendment Provisions*
Exhibit II.B.2(b) -- Automated Provider New Contract*
Exhibit III.B.7 -- Reports-
Exhibit III.C-1 -- Network Standards-
Exhibit III.C-2 -- Customer Support Standards-
Exhibit IV.G -- Average Revenue/Requisition & Monthly
Average Number of Requisitions*
Exhibit V.A. -- Required Maintenance
Exhibit V.B. -- Year 2000 Warranties
Exhibit VII.C-1 -- Current Connectivity Arrangements**
Exhibit VII.C-2 -- Exclusions to Preferred Vendor Status
</TABLE>
* TO BE DELIVERED BY JANUARY 31, 1998.
** TO BE DELIVERED BY JANUARY 15, 1998.
<PAGE>
EXHIBIT A
DEFINITIONS
"AAA" means the American Arbitration Association.
"ActaLab Software" means the ActaLab Software as defined under the
License Agreement.
[*] has the meaning set forth in Section XII.E.6 of the Services
Agreement.
"ActaMed" means ActaMed Corporation, a Georgia corporation.
"ActaMed Gateway shall have the meaning set forth in Section
II.A.1.
"ActaMed Indemnitee" means ActaMed and its directors, officers,
employees, affiliates and permitted assigns.
"ActaMed Network" means the EDI system and network for electronic
Transmissions, which includes the Network Software and ActaMed's gateway and
hardware and computer systems needed to operate that software.
"ActaMed President" shall mean the President of ActaMed, presently
Michael K. Hoover, or should ActaMed be restructured in any manner, the officer
of ActaMed having top authority over ActaMed's operations.
"ActaMed Relationship Manager" shall have the meaning set forth in
Section XI.
"ActaMed Site" means an Automated Provider utilizing the Network
for Lab EDI Services located in a transferred Region that was an SBCL Site on
the Transfer Date of the Region or is a New Site or [*].
"Agreed Services" means all services to be rendered by ActaMed
under this Services Agreement, including without limitation Lab EDI Services.
"Anniversary" shall mean the anniversary date of the Region One
Transfer Date.
"Audit Rights" means the right to, or to have representatives,
(1) examine all books of account, records, reports and
other papers except to the extent that such action would, in the reasonable
opinion of counsel, constitute a waiver of the attorney/client privilege or
violate obligations of confidentiality to third parties,
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-1
<PAGE>
(2) make copies and take extracts from any thereof,
except for information which is subject to a written confidentiality agreement
with a third party,
(3) discuss the affairs, finances and accounts of the
party being audited with such party's officers and independent certified public
accountants (and by this provision such audited party hereby authorizes said
accountants to discuss with the auditing party and its representatives, the
finances and accounts of such entity) and
(4) visit and inspect, at reasonable times and on
reasonable notice during normal business hours, the properties of the other
party;
PROVIDED THAT, the foregoing audit rights are in addition to any rights of a
party under the Georgia Business Corporation Code in the case of ActaMed, or the
Delaware General Corporation Law in the case of SBCL, and shall in no way limit
such rights; and
PROVIDED FURTHER THAT, the expenses incurred in connection with any such
inspection shall be for the account of the auditing party, except that all
reasonable expenses incurred by the audited party, or any of its officers,
employees, agents or independent certified public accountants, shall be
expenses payable by the audited party and shall not be expenses of the auditing
party.
"Automated Provider" means a Provider [*] who or which, on or
after the Transfer Date of the Region in which the Provider [*] is located,
uses the Network to send clinical laboratory test orders to an SBCL Lab or to
receive test result reports from an SBCL Lab.
"Changes" means any improvements, changes or additions to
application software and documentation that improve existing functions, add new
functions, or improve performance through changes in the software or system
design or coding.
"Claim" means any claim for indemnification under Section XIV of
the Services Agreement.
"Claims Notice" means a written notice of an indemnification claim
delivered pursuant to Section XIV of the Services Agreement.
"Confidential Information" means information that is (1)
confidential to the business of a party, including without limitation, data
regarding the extent of the Agreed Services provided hereunder to, or
Transaction Fees, Fixed Fees or PIFs paid hereunder by, SBCL, (2) is designated
and identified as such by such party, and (3) is not a Trade Secret; provided,
however, that Confidential Information does not include any information which is
or becomes generally known to the public without any breach by the Receiving
Party of its duties to the Disclosing Party. Assuming that the foregoing
criteria are met, Confidential Information also includes information which has
been disclosed to a Receiving Party by another person and which the Receiving
Party is obligated to treat as confidential.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-2
<PAGE>
"Customer Support Standards" has the meaning set forth in Section
III.C of the Services Agreement.
"Development Agreement" means the Development Agreement between
SBCL and ActaMed dated October 31, 1997 for the initial development of the
ActaLab Software.
"Disclosing Party" has the meaning set forth in Section X.C of the
Services Agreement.
"Disease Management Business" shall have the meaning set forth in
Section VIII.D.
"Dispute Notice" means a written notice by one party hereto
notifying the other of the existence of a dispute, which notice shall delineate
the disputed items and the factual basis for the dispute.
"Disputing Party" has the meaning given in Section XV.B of the
Services Agreement.
"EDI" means electronic data interchange.
"Exclusive Developments" has the meaning set forth in Section
V.E.1.a of the Services Agreement.
"First Variable Fee" has the meaning set forth in Section IV.C.1 of
the Services Agreement.
"Fixed Fee" means the amounts payable by SBCL pursuant to Section
IV.A of the Services Agreement.
"Fixed Fee Sites" has the meaning set forth in Section IV.G of the
Services Agreement.
"FTE" means "full time equivalent," i.e., the equivalent number of
work hours that would be worked by one person working on a full time basis,
treating eight (8) hours worked per day as a full work day.
"Indemnifying Party" means the Party obligated to provide
indemnification pursuant to Section XIV of the Services Agreement.
"Indemnitee" means an ActaMed Indemnitee or an SBCL Indemnitee.
"Integrity Agreement" means SBCL's Corporate Integrity Agreement
with the OIG.
"Intellectual Property" means copyrights, trademarks, service
marks, trade names, patents, applications therefor, technology rights and
licenses, computer software (including, without limitation, any source or object
codes therefor or documentation relating thereto), computer software licenses,
trade secrets, franchises, know-how, inventions and intellectual property
rights.
A-3
<PAGE>
"Key Performance Standards" shall mean the Performance Standards
under the headings of [*]
"Lab EDI Services " means electronic connectivity services enabling
an Automated Provider to send Transmittal Information electronically to an SBCL
Lab and/or to receive electronically Transmittal Information from an SBCL Lab
utilizing the Network.
"Liability" means any direct or indirect liability, indebtedness,
obligation, expense, claim, deficiency, guaranty or endorsement of or by any
person (other than endorsements of notes, bills and checks presented to banks
for collection or deposit in the ordinary course of business) of any type,
whether accrued, absolute, contingent, matured, unmatured or other.
"License Agreement" means the License Agreement between SBCL and
ActaMed dated the date of the Services Agreement and described in the Preamble
to the Services Agreement.
"Licensed Materials" means the software licensed pursuant to the
License Agreement.
[*] has the meaning set forth in Section XII.E.4 of the Services
Agreement.
"Losses" means any and all demands, claims, actions or causes of
action, assessments, losses, diminution in value, damages (including special and
consequential damages), liabilities, costs, and expenses, including without
limitation, interest, penalties, cost of investigation and defense, and
reasonable attorneys' and other professional fees and expenses.
[*] has the meaning set forth in Section XII.F of the Services
Agreement.
"Network" means the SCAN Network and/or the ActaMed Network.
"Network Software" means ActaMed's personal computer version of the
ProviderLink and ActaLink presentation and network software programs, under
whatever name marketed, and the SCAN Software and the ActaLab Software, and all
Changes to them, which are licensed to Automated Providers and which allow
access to the Network for the transmission of laboratory test order entries and
reception of test result information, or other software program for use by
ActaMed in the transmission of test order entries and reception of test result
information which is licensed to Automated Providers.
"Network Standards" shall have the meaning set forth in Section
III.C of the Services Agreement.
"New Business Plan" shall mean the ActaMed business plan delivered
pursuant to Section 5.1.8 of the Purchase Agreement.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-4
<PAGE>
"New Site" shall mean an ActaMed Site added to the Network on or
after the Transfer Date of the Region in which the ActaMed Site is located and
which is not a Fixed Fee Site.
"Office Space" has the meaning set forth in Section II.B.5 of the
Services Agreement.
"OIG" means the Office of Inspector General, U.S. Department of
Health and Human Services.
"Other Lab" means a commercial laboratory other than an SBCL Lab.
"Oversight Committee" has the meaning set forth in Section III.A of
the Services Agreement.
"Panel" has the meaning given it in Section XV.B of the Services
Agreement.
"PC System" means the personal computer, modem, bar code readers,
bar code label printers, requisition and results printers and other hardware
peripherals required for a Provider to become an Automated Provider.
[*] means an SBCL [*] or other [*].
"Performance Standards" shall have the meaning set forth in Section
III.C of the Services Agreement.
"PIF Amount" has the meaning given it in Section IV.C.2 of the
Services Agreement.
"PIF Number" has the meaning given it in Section III.B.3 of the
Services Agreement.
"PIF Sites" has the meaning given it in Section III.B.3 of the
Services Agreement.
[*] or "PIF" has the meaning given it in Section IV.M.1 of the
Services Agreement.
"Provider" means a physician, clinic, hospital, or other provider
of clinical health care services other than [*].
"Purchase Agreement" means the Asset Purchase Agreement between
ActaMed and SBCL dated the date of the Services Agreement and described in the
Preamble to the Services Agreement.
"Receiving Party" has the meaning given it in Section X.C of the
Services Agreement.
"Region" means any one of Region One, Region Two, Region Three, or
Region Four.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-5
<PAGE>
"Region Four" means the Region described on Schedule 2.2(d) to the
Purchase Agreement.
"Region Four Transfer Date" has the meaning given in Section 2.3.4
of the Purchase Agreement.
"Region One" means the Region described on Schedule 2.2(a) to the
Purchase Agreement.
"Region One Transfer Date" means the date on which Region One is
transferred to ActaMed pursuant to the Purchase Agreement.
"Region Three" means the Region described on Schedule 2.2(c) to the
Assets Purchase Agreement.
"Region Three Transfer Date" has the meaning given in Section 2.3.3
of the Purchase Agreement.
"Region Two" means the Region described on Schedule 2.2(b) to the
Purchase Agreement.
"Region Two Transfer Date" has the meaning given in Section 2.3.2
of the Purchase Agreement.
"Regulation" means any statute, law, ordinance, regulation,
requirement, order or rule of any federal, state, local government or other
governmental agency or body or of any other type of regulatory body, or any
governmental or administrative interpretation of any thereof, including, without
limitation, (i) those covering health, safety, environmental, energy,
transportation, bribery, record keeping, zoning, antidiscrimination, antitrust,
wage and hour, and price and wage control matters, (ii) requirements imposed by
any governmental or regulatory body which must be satisfied to qualify for
Medicare reimbursements, and (iii) any and all federal, state and local health
care laws relating to or covering the methods and ways in which Lab EDI Services
and other related or incidental services or benefits, if any, are provided to
the Automated Providers, including, but not limited to, the Stark law (42 U.S.C.
Section 1395nn) and the Clinical Laboratory Improvements Act of 1988, as
amended.
[*] has the meaning set forth in Section IV.G of the Services
Agreement.
[*] has the meaning set forth in Section IV.G.2 of the Services
Agreement.
"Representatives" means the ActaMed Relationship Manager and the
SBCL Relationship Manager.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-6
<PAGE>
"Requisition" shall mean an electronically transmitted clinical
laboratory test order from an Automated Provider to SBCL which is entered
utilizing SCAN Software, the ActaLab Software or other program for electronic
lab order entry and results reporting and utilizing the Network, for one or
more clinical laboratory tests for a single patient transmitted
electronically at one time and the corresponding test results delivered
electronically to an Automated Provider from SBCL at one or more times. The
term "Requisition" shall include patient eligibility for third party payor
benefits or reimbursement or claim status checking related to such order and
available to ActaMed.
"SBCL" means SmithKline Beecham Clinical Laboratories, Inc., a
Delaware corporation.
"SBCL Access" has the meaning set forth in Section X.B.2 of the
Services Agreement.
"SBCL Indemnitee" means SBCL and its directors, officers,
employees, affiliates and permitted assigns.
"SBCL Lab" means any location at which SBCL or its affiliates
provide, or may in the future provide, clinical laboratory testing services,
regardless of the computer systems or software, if any, used by such lab for lab
order entry and results reporting.
"SBCL President" shall mean the President of SBCL, presently
John B. Okkerse, Jr., Ph.D., or should SBCL be restructured in any manner, the
officer of SBCL having top authority over SBCL's operations.
"SBCL Relationship Manager" has the meaning set forth in Section XI
of the Services Agreement.
"SBCL Site" means an Automated Provider utilizing the SCAN Network
for Lab EDI Services on the Transfer Date of the Region in which such Automated
Provider is located.
"SCAN Assets" has the meaning set forth in the Purchase Agreement.
"SCAN Developments" has the meaning set forth in the License
Agreement.
"SCAN Network" means the SCAN Software and SBCL's gateway and
hardware and computer systems needed to operate the SCAN Software, excluding
[*] which enables Providers or [*] to place laboratory test orders
electronically to an SBCL Lab and/or to receive test result reports
electronically from an SBCL Lab.
"SCAN PSC" means a PSC which utilizes the Network to enter
laboratory test orders electronically and/or to receive test result reports
electronically.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-7
<PAGE>
"SCAN Site" means either an SBCL Site or an ActaMed Site that has
installed and is using SCAN Software for Lab EDI Services.
"SCAN Software" means the SBCL SCAN-TM- software licensed to
ActaMed pursuant to the License Agreement, and all Changes thereto after the
date hereof.
"Second Variable Fee" has the meaning set forth in Section IV.C.2
of the Services Agreement.
[*] has the meaning set forth in Section XII.E.5 of the Services
Agreement.
"SOP" means a standard operating procedure.
"Termination Transition" has the meaning given it in Section XII.D
of the Services Agreement.
"Third Party Claim" means any claim, suit or proceeding (including,
without limitation, a binding arbitration or an audit by any taxing authority)
that is instituted against an Indemnitee by a person or entity other than an
Indemnitor and which, if prosecuted successful, would result in a Loss for which
such Indemnitee is entitled to indemnification hereunder.
"TopLab" means SBCL's proprietary laboratory systems which
facilitate SBCL's internal automated laboratory test processing and reporting,
including but not limited to SBCL's Total Order Processing Laboratory system.
"Trade Secrets" means information related to the Disclosing Party
(1) which derives economic value, actual or potential, from not being generally
known to or readily ascertainable by other persons who can obtain economic value
from its disclosure or use, and (2) which is the subject of efforts by the
Disclosing Party that are reasonable under the circumstances to maintain its
secrecy. Without limitation, for ActaMed, ProviderLink and the ActaLab Software
are Trade Secrets, and for SBCL, the SBCL Software, SCAN Developments and
TopLab are Trade Secrets.
"Transaction Fee Amount" has the meaning set forth in Section
IV.C.1 of the Services Agreement.
"Transaction Fees" has the meaning set forth in Section IV.B of the
Services Agreement.
"Transfer Date" shall mean any one of, and "Transfer Dates" shall
mean more than one of the Region One Transfer Date, the Region Two Transfer
Date, the Region Three Transfer Date, and the Region Four Transfer Date.
"Transferred Employees" shall have the meaning given such term in
the Purchase Agreement.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
A-8
<PAGE>
"Transmission" means the electronic transmittal over the Network of
Transmittal Information in an approved document format.
"Transmittal Information" means information which an Automated
Provider gives ActaMed for communication to SBCL over the Network, or which SBCL
gives ActaMed for communication to an Automated Provider over the Network,
including all copies of same, and including without limitation, data relating to
laboratory records, clinical data, encounter data, test information, test codes
and provider identification numbers (other than UPINs)
"Variable Fees" has the meaning given it in Section IV.C.2 of the
Services Agreement.
A-9
<PAGE>
EXHIBIT II.B.2(a)
LAB EDI SERVICE AGREEMENT AMENDMENT PROVISIONS
III.B.2-1
<PAGE>
EXHIBIT II.B.2(b)
LAB EDI SERVICE AGREEMENT
III.B.7-1
<PAGE>
EXHIBIT III.B.7
REPORTS
A. REPORTS ACTAMED WILL PROVIDE TO SBCL
The following reports will be provided to SBCL by ActaMed on the
indicated schedule.
1. BILLING REPORTS
a. [*] SUMMARY REPORTS (POST-ACTAMED GATEWAY):
(1) Fixed Fee Sites
(a) Total Sites
(b) Total Requisitions
(c) Average Requisitions per Site
(2) Transaction Fee Sites
(a) Total Sites
(b) Total Requisitions
(c) Average Requisitions per Site
(3) PIF Sites
(a) Total Sites charged for the [*] that [*]
(with appropriate supporting detail)
(4) Label Printer Fees
(a) Total Sites charged for the Label printer
equipment fee (with appropriate supporting
detail)
b. [*] DETAILED FEES:
(1) List of Fixed Fee sites by lab
(2) List of Transaction Fee sites by lab
III.B.7-1
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
<PAGE>
(3) List of PIF Sites by lab
(4) List of sites with bar code printer paid by SBCL by
lab
c. CUSTOM DEVELOPMENT:
(1) Monthly itemization and accounting for the hours
worked for any projects active under a Custom
Development Fee, and a project status report on each
item worked
d. MONTHLY EXPENSE BILLINGS:
(1) Personnel in non-transferred regions, with
supporting detail
2. PERFORMANCE REPORTS
a. All reports necessary to verify and measure the
Performance Standards, including, but not limited to, the
following: (i) [*] help desk REPORTS, as set forth
in Exhibit III.C-2 - Customer Support Standards showing
performance statistics against the Performance Standards
and the number of calls received by type of problem
(detail problem coded); (ii) [*] network reports, as
set forth in Exhibit III.C-1 - Network Standards; (iii)
Performance Metrics reports against the Performance
Standards described in Exhibit III.C-1 & 2, including
comparison of actuals to standard for current month and
rolling prior 12 months.
b. Transfer BENCHMARK reports, as set forth in Exhibit
2.3.1(a) of the Assets Purchase Agreement.
c. Monthly Gateway reports (format to be mutually determined
once the ActaMed GATEWAY is active, but intended to be
generally similar to the SBCL November 1997 Gateway
Report).
d. As APPROPRIATE from time to time, in light of
technological advances, market conditions or industry
standards or other facts and circumstances, a report
describing ActaMed's plans to increase the performance
and capabilities of the Network and to improve Customer
Service beyond the minimum levels specified in Exhibits
III.C-1 and III.C-2.
e. Monthly report of SBCL clients that have deinstalled
(discontinued to use) Lab EDI Services.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
III.B.7-2
<PAGE>
f. An ongoing data base (to be created, kept current and
available for reporting) report of the current list of
clients approved for installation including date
received, Lab, Client ID, Client demographics and
expected date of installation.
3. SAS 70 REPORT
ActaMed will provide a report produced in accordance with
standards established by the American Institute of Certified Public Accountants'
Statement on Auditing Standards Number 70: Reports on the Processing of
Transactions by Service Organizations. ActaMed shall submit the first such
report to SBCL by the end of 1998.
B. REPORTS SBCL WILL PROVIDE TO ACTAMED
1. BILLING REPORTS
A. SBCL WILL MAKE AVAILABLE TO ACTAMED ACCESS TO DATA
RELATING TO:
(1) Fixed Fee Sites
(2) Total Sites (list of Fixed Fee Sites by Lab active
that month)
(3) List of Transaction Fee sites by Lab
B. FOLLOWING ACTAMED GATEWAY, MONTHLY EXPENSE BILLINGS (with
appropriate SUPPORTING detail):
(1) Gateway 1-800 charges to ActaMed
(2) Non-transferred local line charges
(3) Service Fees for ongoing support of ActaMed Gateway,
if any
(4) Service Fees for SBCL Gateway Services for
Transferred Sites, if any
2. PERFORMANCE REPORTS
a. Prior to the ActaMed Gateway, SBCL will continue to
provide ActaMed with copies of its standard monthly
Gateway report.
b. Timely reports on changes in SBCL that affect ActaMed and
its PERFORMANCE hereunder, as set forth in Section IX.
III.B.7-3
<PAGE>
3. STRATEGIC INFORMATION
Quarterly information on major trends within SBCL as
appropriate that are relevant to ActaMed and its performance hereunder, such as
new customers, lost customers, trends in lab requisition and result volumes,
compliance related issues, etc.
III.B.7-4
<PAGE>
EXHIBIT III.C-1
NETWORK SUPPORT STANDARDS
ACTAMED NETWORK AVAILABILITY
The ActaMed Network will be available 24 hours a day, 7 days a week with the
exception of Planned Down Hours. "Planned Down Hours" means that time which is
reasonably required for maintenance and problem resolution as reasonably
required and notwithstanding any other provision herein shall only occur during
the hours of [*] or on Federally recognized holidays.
HARDWARE AND MODEM AVAILABILITY
For each month, ActaMed shall maintain an "Availability Percentage" of at
least [*]. Hardware systems and modems are operational and available for
receiving/accepting calls as measured by an ActaMed systems management and
monitoring tool [*]. Hardware specifically includes the ActaMed host
machines required to process Lab EDI Services transactions, ActaMed
provisioned modems and circuit termination equipment servicing Automated
Providers using the ActaMed Network, and other third party provisioned
dial-in access service and devices relevant to the Lab EDI Services.
The "Availability Percentage" for Lab EDI Services shall be calculated on [*]
and will be based on data gathered through an automated Systems Management
and Reporting tool [*]. Similar automated measurement and reporting will be
implemented as soon as is practical for SCAN Sites transferred to the ActaMed
Gateway, but not later than 180 days following such transfer of the first
SCAN Site to the ActaMed Gateway. The Availability Percentage is calculated
as set forth below:
- Defined Hours are the total days in the month multiplied by 24
hours.
- Unplanned Hours are the hours experienced during the month in
which the ActaMed Network is not operable or otherwise not properly
transmitting valid Transmission as provided in the Agreement
excluding Planned Down Hours.
- Actual Hours are the Defined Hours minus the Unplanned Hours.
- Availability Percentage is determined by dividing the Actual Hours
by Defined Hours and multiplying the result by 100.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
III.C-1-1
<PAGE>
SUCCESSFULLY DELIVERED CALLS
For each month, ActaMed shall maintain a "Successfully Delivered Call
Percentage" of at least [*]. The "Successfully Delivered Call Percentage" is
the total of all Successfully Delivered Calls divided by the total of attempted
calls from all sources and multiplying the result by 100.
A Successfully Delivered Call shall mean a call made to ActaMed's premise
equipment from any source for the purpose of processing Lab EDI Services. as to
which ActaMed's equipment successfully offers service, to be measured by the
call service provider's equipment facilities including:
- calls delivered by an Interexchange Carrier ("IXC"), such as
Sprint, AT&T, Worldcom, etc., using toll-free dial-in service to
will be measured by the IXC carrier switch;
- calls delivered by a third party dial-in access provider will be
measured by the management capabilities of that provider's modem
pool; and
- calls delivered by a local service provider or by dedicated
toll-free dial-in service will be measured by ActaMed's
terminating premise equipment.
MODEM CONNECTIVITY
For each month, ActaMed shall maintain a "Modem Connectivity Percentage" of at
least [*]. The "Modem Connectivity Percentage" is determined by dividing the
total number of Successfully Connected Calls by the total of Successfully
Delivered Calls and multiplying the result by 100.
A Successfully Connected Call is a Successfully Delivered Call that establishes
and maintains successful modem connection as determined by the statistics
generated by the management and reporting functionality of the ActaMed
terminating modem bank and/or third party dial-in access equipment.
TRANSACTION PROCESSING
ActaMed acknowledges and agrees that all Transactions meeting the
requirements set forth next to one or both of the bullet points below
("Proposed Transaction") will be processed by the ActaMed Network. If
Proposed Transactions are not being processed by the ActaMed Network, it will
be treated as a Severity 1 problem. It is expected by the Parties that [*]
of connected and Proposed Transactions will be successfully processed within
ActaMed Network.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
III.C-1-2
<PAGE>
- Any order transactions that are entered according to the applicable
specifications and edits of the Lab EDI software such as SCAN Software
or ActaLab Software or any other ordering software module approved by
ActaMed and SBCL that is connected to the ActaMed Network for the
purposes of entering lab orders and upon completion of the order entry
indicates to the operator that the order has been accepted for
Transmission to SBCL; and
- Any result transactions transmitted by SBCL systems in accordance with
applicable specifications and containing sufficient information to allow
the ActaMed Network to determine the approved system to which the
transaction is to be delivered.
[*]
[*] The Parties agree that this is not a currently automated measurement and
is not included as a requirement of Section III.B.7, Reports.
HISTORICAL DATA FOR RE-TRANSMISSION
ActaMed will store all result transmission data on, and make it available in
accordance with the Services Agreement via, the ActaMed Gateway for a minimum of
[*].
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
III.C-1-3
<PAGE>
EXHIBIT III.C-2
CUSTOMER SUPPORT STANDARDS
ACTAMED HELP DESK
The ActaMed Help Desk for all Lab EDI Services will be staffed Monday through
Friday 8:00 AM to 8:00 PM EST excluding federally recognized holidays. Issues
of any severity level can be reported during this time via any one of the
following methods:
- Telephone via ActaMed toll-free service (800 line);
- FAX;
- Internet e-mail to ActaMed help desk personnel; or
- Internet e-mail directly into the ActaMed Help Desk call tracking
system.
In addition,
- Internet web pages are being constructed to answer frequently asked
questions;
- By special arrangement, limited direct access to the ActaMed Help
Desk call tracking system is possible; and
- Using Internet e-mail and the assigned tracking number, the status
of calls can be retrieved at any time.
There shall be after hours support, which is typically limited to issues that
are defined as Severity 1 or Severity 2 as further defined below. These are
either issues that involve multiple users and major communications or systems
failures, or problems involving an outage of a single Automated Provider
(i.e. non-critical issues such as training questions, enhancement requests
and usage questions are usually handled during normal help desk hours.)
Service is initiated by calling the main Help Desk 800 number and leaving a
detailed message. Voice mail left after hours or on holidays will result in a
page to the appropriate on call analyst who will retrieve the message and
return the call and immediately initiate investigatory and corrective actions
as appropriate in accordance with Severity Levels.
III.C-2-1
<PAGE>
CALL TRACKING
Beginning at such time as the ActaMed SCAN help desk begins to accept client
calls from ActaMed Sites, which shall occur at a date mutually agreed upon by
the parties, all calls made to the ActaMed SCAN Help Desk will be logged into
ActaMed's "Support Magic" call tracking system, and will include at a minimum
the following information:
- Site ID (Machine ID)
- Site Name
- Caller Name
- Phone Number
- Local Lab
- Date of Call
- Time of Call
- Problem Code / Description
- Call Recipient / Analyst
- Problem Definition
- Call Status
- Solution Code / Clear Description of final resolution
- Severity Code
- Date and time of final resolution
ActaMed shall be responsible only for calls related to ActaMed Sites. Calls
from all other SCAN sites will continue to be supported by SBCL and will
continue to be tracked by SBCL processes as in force at that time.
SEVERITY CODES
Help Desk calls will be logged and appropriate escalations will be made based
upon severity codes assigned to each call. It is the responsibility of the
analyst handling the call to assign the severity level in accordance with the
severity level definitions described below. The definition of each
III.C-2-2
<PAGE>
severity level and the classification of call types into severity levels will
initially be as set forth below, with more specific definitions to be
determined through negotiation between ActaMed and SBCL. The definitions may
be reassessed and are subject to change by mutual consent of the Parties.
The ActaMed Help Desk's method of classifying calls into priority levels will
be reviewed periodically with the Oversight Committee. SBCL will be
responsible for defining additional situations and communicating to ActaMed
any requests on how to classify particular call situations.
SEVERITY 1
DEFINITION: A critical system or component is down or experiencing
degraded service causing SBCL or a customer's business functions to be
halted. Severity I issues will typically involve major system outages
that affect the service provided to many users.
REQUIRED ACTION: Immediate notification to those persons identified in
the Crisis Management document. [*] of Severity 1 issues should be
resolved within [*] with [*] updates between ActaMed and SBCL.
SEVERITY 2
DEFINITION: A single user is down; a component is experiencing degraded
service; consumable supplies are unavailable and does not have a
critical impact on the business, but may restrict function to some users
and may impact normal business operations.
REQUIRED ACTION: The help desk will asses the situation and verify that
setup or configuration problems are not the cause. After the original
assessment has been made, an ActaMed CIS representative will normally be
dispatched to correct or replace the failing component. In remote areas
where localized support is not available, a replacement component will
be shipped for next day delivery, and arrangements will be made to
provide assistance setting up or installing that component.
Arrangements will also be made to remove or arrange for the removal of
the failed component. [*] of Severity 2 calls should be resolved within
[*] with updates to the affected user every [*] or less.
SEVERITY 3
DEFINITION: A user's system is still operating but is experiencing
difficulties or a specially requested deliverable is unavailable.
REQUIRED ACTION: The Help Desk will make every attempt to resolve the
issue over the phone or using the tools available to them. If those
attempts are not successful, a ActaMed CIS representative might be
called upon to resolve the issue on site, but these issues will
typically have a lower priority than the Severity 2 issues listed above.
[*] of Severity 3 calls will be resolved within [*] with updates to
the affected user every [*] or less.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
III.C-2-3
<PAGE>
NEW SITE INSTALLATION
In accordance with the agreed upon procedures for installing New Sites (or [*]
Sites) that SBCL requests or approves for Lab EDI Services, ActaMed will:
- If required, phone line installation and new service will be
ordered on behalf of the Provider or SBCL on average within [*] of
receipt of new site notification and,
- Provide installation and training, including any hardware required
under Section IV.L of the Services Agreement, to properly prepare
and set up the new client to use Lab EDI Services within [*] of
receipt of new site notification and phone line availability; or
- PIF Sites will be installed within [*] from the time the
notification is received and phone service is available.
except that, (i) delays caused by the practice management system vendor or the
Provider, shall not be the responsibility of ActaMed; and (ii) SBCL and ActaMed
will, when necessary, cooperate in the development of site installation
schedules to reflect periods of high volumes of new installations and remote
installations (usually requiring air travel).
DE-INSTALLATIONS
When required by the Assets Purchase Agreement or this Agreement, ActaMed
will deinstall any Automated Provider within [*] of receipt of SBCL's
deinstallation request. Re-deployment of the deinstalled PC System for Lab
EDI Services will be in accordance with Section IV of the Services Agreement
and in accordance with the performance metrics of a New Site.
RETAINING
ActaMed will provide ongoing training support in a manner and at such frequency
as is reasonably required to maintain client satisfaction and ability to
continue to use Lab EDI Services effectively to process laboratory transactions.
SCAN CONSUMABLE SUPPLIES
ActaMed will provide, [*] consumable supplies required by all ActaMed Sites
for use of Lab EDI Services including printer paper, toner cartridges, backup
tape cartridges and labels that meet SBCL label specifications. ActaMed will
deliver or arrange for delivery of these as required for uninterrupted use of
Lab EDI Services. Client requests for such supplies that prevent use of Lab
EDI Services will be considered a Severity [*] problem.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
II.C-2-4
<PAGE>
MEASUREMENTS AND REPORTING
Measurement will begin when the problem is received by the ActaMed Help Desk at
which time it will be recorded into the computerized on-line problem management
tool. Measurement will end when the call is resolved satisfactorily and closed
by the ActaMed Help Desk representative. In the case of calls that have been
forwarded to an SBCL facility for questions or issues not covered by the ActaMed
Help Desk, the ActaMed Analyst will, except in those cases where the problem
determination or resolution is clearly the responsibility of SBCL because of the
nature of the call, take ownership of that call and follow it through any other
path it may take. So long as SBCL provides the information needed to resolve
such a call, ActaMed will also be made to document that call and close it out
with a detailed explanation of the final resolution. Where it is not possible
for the ActaMed Analyst to remain "on the call", it is the responsibility of the
SBCL personnel to notify the ActaMed Help Desk if the outcome is to be
documented in the help desk system.
Other measurements that will be made available on a monthly basis will come from
the ACD system. The variety of reports available based upon the call tracking
system and the ACD statistics will include:
<TABLE>
<CAPTION>
REPORT TARGET SERVICE LEVEL
------ --------------------
<S> <C>
Number of calls by category N/A, will vary
Calls by region N/A, will vary
Abandoned call rate *
Average hold time [*]
</TABLE>
* since there is no currently available SBCL baseline to be used to set
reasonable standards, ActaMed will record these metrics from the beginning of
its operations of the help desk. After the first four months of help desk
operation, ActaMed and SBCL will evaluate performance and set mutually-agreeable
metrics based on SBCL's actual performance and generally accepted performance
standards for similar services. In no case shall such metrics result in
standards lower than those generally found in the industry for similar services.
The percent of calls closed within the time frame objectives will be measured by
calculating, by priority level, the volume of calls closed within the time frame
objectives as a percentage of total calls opened.
The ActaMed Help Desk will use best efforts to accommodate any requests for
additional information as long as the collection of the information does not add
significant time and effort in logging the call. The ActaMed Help Desk
statistics will be reported to SBCL on a monthly basis. The means of
distribution is yet to be determined.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
III.C-2-5
<PAGE>
SATISFACTION LEVELS
For each year during the term of the Services Agreement, ActaMed will perform
client satisfaction surveys assessing Automated Providers' satisfaction with
ActaMed's Lab EDI Services. The format and content of the annual surveys shall
be determined by ActaMed except that ActaMed will afford SBCL reasonable
opportunity to review and comment thereon prior to its use. The annual survey
will be conducted at annual intervals.
III.C-2-6
<PAGE>
EXHIBIT IV.I
AVERAGE REVENUE/REQUISITION & MONTHLY
AVERAGE NUMBER OF REQUISITIONS
IV.I-1
<PAGE>
EXHIBIT V.A
MAINTENANCE
ActaMed will provide SBCL with the following hardware, network and application
(product) maintenance services which will be performed by ActaMed staff not
dedicated to SBCL enhancements. The cost of these maintenance services are
provided as a part of the annual Fixed Fee and Transaction Fees, and include the
following:
PRODUCT MAINTENANCE
- Maintenance of the Network through both emergency and routine bug fixes
and scheduled maintenance releases;
- Such changes and modifications to the Network required to manage
scalability and capacity issues associated with increased transaction
volumes;
- Provision of routine, updated application documentation and training
materials;
- Provision of periodic product updates to improve usability and to
improve existing features and functionality.
PERFORMANCE
- Maintenance, monitoring and reporting of hardware, network and
communication systems regarding stability and performance as specified
in Exhibit III.C-1 Network Standards;
- Changes required to maintain above service level commitments, including
changes and modifications required to manage scalability and capacity
issues associated with increased transaction volumes;
- Technology upgrades to the Network (to include such things as fault
tolerance produces and services) will be included as part of ongoing
maintenance; and
- Maintenance of appropriate connectivity to SBCL host systems to maintain
security provisions and the data integrity of Transmissions.
IV.I-2
<PAGE>
EXHIBIT V.B
YEAR 2000 WARRANTIES
ActaMed warrants that the SCAN Software and ActaLab Software as compiled on any
hardware and operating system platform designated in its documentation
("Platforms") will satisfy all of the following:
(a) Such software will properly process date-related information
from different centuries (19th through 21st). Results utilizing such software
will be consistent and correct whether or not dates being processed span
different centuries and will be given with the proper indication of century.
(b) Data involving date information which will be generated from
use of the software will be coded in a manner that captures, stores and displays
date-related information so that the software will properly access and process
the data regardless of the century involved.
(c) The software will properly process date-related data which had
been generated by previous versions of thereof regardless of the century
involved.
(d) The software interfaces with the operating system and other
software, and with devices, will properly exchange and use date-related
information regardless of the century involved, so long as such other software,
systems and devices provide date-related information in a compatible format.
(e) The software will check any date-related information provided
by the user, and by any devices, systems or software with which the software
interfaces, and will reject any date-related information which is not provided
in a format which the software will properly process. When data is rejected, the
software will generate an explanatory error message.
(f) The software will not have a feature which will cause it to
stop operating or to limit or alter its functions or performance because of a
date or time extending beyond 11:59:59 p.m. on December 31, 1999.
(g) The software will process information relating to years
beginning with 2000 properly, including recognizing that the year 2000 and every
fourth year thereafter is a leap year.
(h) The software (including but not limited to, runtime systems)
will function correctly if executing at the moment when the year changes from
1999 to 2000. The software setup and updates will not be affected by the
century change.
V.B-1
<PAGE>
EXHIBIT VII.C-1
CURRENT CONNECTIVITY ARRANGEMENTS
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Production No No Yes No Computer Based Patient Record
[*] Specs Sent No No Yes No Physician Practice
[*] Dormant No No No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Dormant No Yes No No CLinic
[*] Letter Sent No No Yes No Physician Practice
[*] Production No No Yes No Vendor Lab
[*] Production No Yes No No Medical Network
[*] Specs Sent No Yes No No CLinic
[*] Specs Sent No Yes No No Physician Practice
[*] Production No Yes No No ESRD
[*] Dormant No No Yes No Medical Network
[*] Specs Sent No No Yes No Medical Network
[*] Specs Sent No No No No Unknown
[*] Letter Sent No No No No Unknown
[*] Production No Yes No No Physician Practice
[*] Specs Sent No No No No Unknown
[*] Production No No No No Unknown
[*] Dormant No Yes No No Unknown
[*] Letter Sent No Yes No No Physician Practice
[*] Dormant No Yes No No Unknown
[*] Specs Sent No No No No Unknown
[*] Dormant No Yes No No Unknown
[*] Letter Sent No Yes No No CLinic
[*] Specs Sent No No No No Unknown
[*] Dormant No Yes No No ESRD
[*] Specs Sent No Yes No No CLinic
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-1
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Dormant No Yes No No Physician Practice
[*] Dormant No Yes No No Physician Practice
[*] Specs Sent No No No No Unknown
[*] Specs Sent No Yes No No Unknown
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No No No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No Yes No No Unknown
[*] Production No No Yes No Physician Practice
[*] Dormant No Yes No No Unknown
[*] Dormant No Yes No No Unknown
[*] Production No No Yes No Physician Practice
[*] Dormant No Yes No No Physician Practice
[*] Production No Yes No No Physician Practice
[*] Beta No Yes No No Charting Program
[*] Specs Sent No Yes No No Unknown
[*] Section I Sent No No No No CLinic
[*] Specs Sent No No Yes No Unknown
[*] Specs Sent No Yes No No ESRD
[*] Specs Sent No Yes No No Physician Practice
[*] Dormant No Yes No No CLinic
[*] Dormant No Yes No No CLinic
[*] Dormant No Yes No No Nursing Home
[*] Development No Yes No No Computer Based Patient Record
[*] Specs Sent No No No No Unknown
[*] Production No Yes No No ESRD
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-2
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Specs Sent No Yes No No Physician Practice
[*] Production No Yes No No CLinic
[*] Dormant No No No No Unknown
[*] Specs Sent No Yes No No Unknown
[*] Specs Sent No No No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Development No No Yes No Physician Practice
[*] Production No Yes No No Unknown
[*] Production No Yes No No Physician Practice
[*] Specs Sent No No Yes No Unknown
[*] Specs Sent No Yes No No Physician Practice
[*] Production No Yes No No Unknown
[*] Dormant No Yes No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Dormant No Yes No No CLinic
[*] Specs Sent No No Yes No CLinic
[*] Specs Sent No Yes No No Unknown
[*] Dormant No Yes No No CLinic
[*] Dormant No Yes No No Physician Practice
[*] Production No Yes No No Physician Practice
[*] Letter Sent No Yes No No Physician Practice
[*] Production No Yes No No Physician Practice
[*] Production No No Yes No Occupational Health
[*] No No No No Unknown
[*] Production No Yes No No Unknown
[*] Dormant No Yes No No Vendor Lab
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-3
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Production No Yes No No Medical Network
[*] Production No Yes No No Medical Network
[*] Dormant No No Yes No Medical Network
[*] Dormant No No Yes No Medical Network
[*] Development No No Yes No Medical Network
[*] Specs Sent No No Yes No Physician Practice
[*] Dormant No Yes No No CLinic
[*] Specs Sent No Yes No No CLinic
[*] Specs Sent No Yes No No CLinic
[*] Letter Sent No No No No Unknown
[*] Specs Sent No No No No Unknown
[*] Specs Sent No No Yes Yes Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Production No Yes No No CLinic
[*] Specs Sent No No Yes No Interface Engine
[*] Dormant No Yes No No Unknown
[*] Specs Sent No Yes No No Medical Network
[*] Specs Sent No Yes No No Unknown
[*] Specs Sent No No No No Physician Practice
[*] Specs Sent No No Yes No Interface Engine
[*] Specs Sent No No No No Unknown
[*] Dormant No No No No Unknown
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No No No No Unknown
[*] Specs Sent No Yes No No CLinic
[*] Specs Sent Yes No No No Physician Practice
[*] Dormant No Yes No No Unknown
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-4
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Production No Yes No No Physician Practice
[*] Dormant No Yes No No Physician Practice
[*] Production No No Yes Yes Medical Network
[*] Production No Yes No No ESRD
[*] Specs Sent No Yes No No Unknown
[*] Specs Sent No No No No Unknown
[*] Development No Yes No No Unknown
[*] Dormant No Yes No No ESRD
[*] Specs Sent No Yes No No Physician Practice
[*] Development No Yes No No Physician Practice
[*] Specs Sent No No Yes No Physician Practice
[*] Production No Yes No No Medical Network
[*] Specs Sent No No No No Unknown
[*] Specs Sent No Yes No No Clinical Trials
[*] Letter Sent No No No No Unknown
[*] Development No No Yes No Medical Network
[*] Production No No Yes No Occupational Health
[*] Development No Yes No No Physician Practice
[*] Beta No Yes No No Physician Practice
[*] Specs Sent No No Yes No Medical Network
[*] Specs Sent No Yes No No CLinic
[*] Specs Sent No Yes No No Physician Practice
[*] Development Yes No No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Development No No Yes No Physician Practice
[*] Letter Sent No Yes No No Physician Practice
[*] Production No Yes No No Physician Practice
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-5
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Specs Sent No No No No Physician Practice
[*] Dormant No Yes No No Vendor Lab
[*] Specs Sent No Yes No No CLinic
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No Yes No No Medical Network
[*] QA No No Yes Yes Physician Practice
[*] Production No Yes No No Physician Practice
[*] Specs Sent No No Yes No CLinic
[*] Specs Sent No No Yes No Physician Practice
[*] Specs Sent No Yes No No Unknown
[*] Production No No Yes Yes Physician Practice
[*] Letter Sent No No No No Unknown
[*] Dormant No Yes No No Unknown
[*] Dormant No Yes No No Unknown
[*] Dormant No Yes No No Unknown
[*] Specs Sent No No No No Unknown
[*] Production No Yes No No Physician Practice
[*] Production No No Yes No ESRD
[*] Dormant No Yes No No Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Beta No Yes No No Physician Practice
[*] Specs Sent No Yes No No Unknown
[*] Letter Sent No Yes No No Unknown
[*] Development No No Yes No Unknown
[*] Specs Sent No Yes No No Physician Practice
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-6
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No Yes No No Unknown
[*] Dormant No No Yes No Vendor Lab
[*] Letter Sent No No Yes No Physician Practice
[*] Letter Sent No Yes No No Medical Network
[*] Dormant No No No No Unknown
[*] Specs Sent No No Yes No Vendor Lab
[*] Specs Sent No No Yes No Computer Based Patient Record
[*] Specs Sent No No No No Physician Practice
[*] Development No Yes No No Physician Practice
[*] No Yes No No Unknown
[*] Specs Sent No No No No Unknown
[*] Production No No Yes No Vendor Lab
[*] No Yes No No ESRD
[*] Specs Sent No Yes No No Pharmaceutical Services
[*] Production No Yes No No Physician Practice
[*] Production No No Yes No CLinic
[*] Development No No No No Unknown
[*] Production No Yes No No Unknown
[*] Development No Yes No No ESRD
[*] Dormant No Yes No No Physician Practice
[*] Development No No Yes No Unknown
[*] Dormant No No No No Medical Network
[*] No No No No Unknown
[*] Dormant No Yes No No CLinic
[*] Specs Sent No Yes No No Pharmaceutical Services
[*] Specs Sent No Yes No No Unknown
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-7
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Specs Sent No Yes No No Physician Practice
[*] Production No Yes No No Physician Practice
[*] Dormant No Yes No No Physician Practice
[*] Dormant No No Yes No Nursing Home
[*] Specs Sent No Yes No No Unknown
[*] Development No No Yes No Physician Practice
[*] Specs Sent No No No No Unknown
[*] Production No Yes No No Physician Practice
[*] No No No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Specs Sent No No No No Unknown
[*] Specs Sent No No No No Unknown
[*] Section I Sent No No No No Unknown
[*] Production No Yes No No Physician Practice
[*] Specs Sent No Yes No No Physician Practice
[*] Specs Sent No No Yes No Unknown
[*] Specs Sent No No Yes No Unknown
[*] Specs Sent No Yes No No Physician Practice
[*] Production No Yes No No ESRD
[*] Specs Sent No No No No Unknown
[*] Production No Yes No No Physician Practice
[*] Specs Sent No Yes No No CLinic
[*] Dormant No Yes No No Unknown
[*] Specs Sent No Yes No No CLinic
[*] Letter Sent No Yes No No ESRD
[*] Production No No Yes Yes Unknown
[*] Dormant No Yes No No Unknown
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-8
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Production No Yes No No Nursing Home
[*] Dormant No Yes No No Physician Practice
[*] Specs Sent No Yes No No Unknown
[*] Beta No No Yes No Vendor Lab
[*] Specs Sent No No No No Unknown
[*] Development No Yes No No Physician Practice
[*] Specs Sent No Yes No No CLinic
[*] Dormant No No Yes No CLinic
[*] Development No Yes No No Unknown
[*] Dormant No No Yes No Unknown
[*] Specs Sent No No No No Unknown
[*] Dormant No Yes No No Physician Practice
[*] Dormant No Yes No No Unknown
[*] Specs Sent No No Yes No Physician Practice
[*] No No No No Unknown
[*] Letter Sent No Yes No No CLinic
[*] Specs Sent No No No No Unknown
[*] Dormant No No Yes No Unknown
[*] Specs Sent No Yes No No CLinic
[*] No No Yes No CLinic
[*] Dormant No Yes No No CLinic
[*] Dormant No Yes No No CLinic
[*] Production No Yes No No ESRD
[*] Specs Sent No No Yes No CLinic
[*] Specs Sent No Yes No No Unknown
[*] Production No Yes No No Unknown
[*] Dormant No Yes No No CLinic
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-9
<PAGE>
EXISTING VENDOR INTERFACE RELATIONSHIPS
<TABLE>
<CAPTION>
ORDERS RESULTS ORDERS AND
VENDOR NAME STATUS ONLY ONLY RESULTS BILLING DESCRIPTION
------------- -------------------- -------- --------- -------------- --------- ----------------------------------
<S> <C> <C> <C> <C> <C> <C>
[*] Specs Sent No No Yes No Unknown
[*] Dormant No Yes No No Medical Network
[*] Specs Sent No No No No Unknown
[*] Specs Sent No No Yes No Physician Practice
</TABLE>
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
VII.C-1-10
<PAGE>
AMENDMENT NO. 1 TO
SERVICES AGREEMENT
This AMENDMENT NO. 1 TO SERVICES AGREEMENT ("Amendment No. 1") is
made and entered into this 15th day of May, 1998 by and between ACTAMED
CORPORATION, a Georgia Corporation ("ActaMed") and SMITHKLINE BEECHAM
CLINICAL LABORATORIES, INC., a Delaware Corporation ("SBCL").
WHEREAS, ActaMed and SBCL entered into a Services Agreement on
December 31, 1997 ("Services Agreement") and desire to amend same in connection
with the merger a subsidiary of Healtheon Corporation with and into ActaMed,
with the result that ActaMed will become a wholly-owned subsidiary of Healtheon.
NOW THEREFORE, in consideration of the premises and the mutual
promises contained herein, the parties, intending to be legally bound, agree as
follows:
1 DEFINITIONS.
Capitalized terms used in this Amendment No. 1 and not otherwise defined
herein have the meanings set forth in the Services Agreement.
2 AMENDMENTS.
2.1 [*] REMOVED FROM [*]. Section IV.C is replaced in its entirety as
follows:
"1. An amount (the "FIRST VARIABLE FEE") equal to (i) [*]
minus the aggregate of the amount billed to SBCL pursuant to Section
IV.B. above, excluding amounts attributable to any Provider office with
ProviderLink that is subsequently installed with the Scan Software or
ActaLab Software (the "FIRST TRANSACTION FEE AMOUNT") prior to the [*]
(ii) [*] minus the sum of (A) the First Transaction Fee Amount for the
period from the date hereof to the [*] and (B) the amount paid pursuant
to clause (i) above; and (iii) [*] minus the sum of (A) the First
Transaction Fee Amount for the period from the date hereof to the [*] and
(B) the amount paid pursuant to clauses (i) and (ii) above.
2. An amount (the "SECOND VARIABLE FEE") equal to (i)
[*] minus the aggregate of the amount paid plus amounts owed (whether or
not billed) pursuant to Section IV.M.1 below (the
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
<PAGE>
"PIF AMOUNT") prior to the [*]; (ii) [*] minus the sum of (A) the PIF
Amount for the period from the date hereof to the [*] and (B) the amount
paid pursuant to clause (i) above; and (iii) [*] minus the sum of (A) the
PIF Amount for the period from the date hereof to the [*] and (B) the
amount paid pursuant to clauses (i) and (ii) above; PROVIDED THAT if the
PIF Amount with respect to an annual period (other than the last such
annual period) is at least [*] of the aforementioned dollar amount for
that annual period, no payment shall be due under this Section IV.C.2 for
such annual period.
3. An amount (the "THIRD VARIABLE FEE" and together
with the First Variable Fee and Second Variable Fee, the "VARIABLE
FEES") equal to (i) [*] minus the aggregate of the amount billed to SBCL
attributable to any Provider office with ProviderLink that is
subsequently installed with the Scan Software or ActaLab Software (the
"THIRD TRANSACTION FEE AMOUNT") prior to the [*]; (ii) [*] minus the sum
of (A) the Third Transaction Fee Amount for the period from the date
hereof to the [*] and (B) the amount paid pursuant to clause (i) above;
and (iii) [*] minus the sum of (A) the Third Transaction Fee Amount for
the period from the date hereof to the [*] and (B) the amount paid pursuant
to clauses (i) and (ii) above.
4. Subject to Section IV.D, the Variable Fees shall be
paid annually within thirty (30) days after invoice therefor from
ActaMed or Healtheon, which shall be (i) submitted to SBCL within [*]
(ii) detail the calculation thereof, and (iii) reflect the Variable Fees
payable in respect of the most recently completed annual period only.
SBCL shall have Audit Rights with respect to any disputed amount of the
Variable Fees."
2.2 CONDITIONS TO BUSINESS ASSURANCE PAYMENTS. Section IV.D.1 is
hereby replaced in its entirety as follows:
"1. With respect to all Variable Fees, (i) such fees shall
cease to be payable if ActaMed shall fail to satisfy any of the Key
Performance Standards, or (ii) such fees (excluding the portion of the
First Variable Fee attributable to Transaction Fees generated from PIF
Sites) for the applicable year shall not be payable (but shall be
treated as paid for purposes of calculation of any amount payable in
the following year) if any of the following shall occur:
a. As of [*] ActaMed shall fail to have at least [*]
ActaMed Sites;
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-2-
<PAGE>
b. As of [*] ActaMed shall fail to have at least [*]
ActaMed Sites; and
c. As of [*] ActaMed shall fail to have at least [*]
ActaMed Sites.
2.3 CONDITIONS TO BUSINESS ASSURANCE PAYMENTS. Section IV.D is hereby
further amended by adding the following Subsection 3 at the end of such Section:
"3. With respect to the Third Variable Fee, such fees also
shall not be payable (but shall be treated as paid for purposes of
calculating any amount payable in the following year) if any of the
following shall occur:
a. As of [*] ActaMed shall fail to have at least [*]
ActaMed Sites;
b. As of [*] ActaMed shall fail to have at least [*]
ActaMed Sites; and
c. As of [*] ActaMed shall fail to have at least [*]
ActaMed Sites.
2.4 [*] COSTS. Section IV.J is amended to insert at the end thereof:
"SBCL is not responsible for paying any [*] incurred by ActaMed or a Provider
relating to the provision of Lab EDI Services, including without limitation,
any [*], [*] and [*]."
2.5 REMOVAL OF [*] HARDWARE PURCHASES. Section IV.K.2.b is
replaced in its entirety as follows:
"b. In addition, ActaMed shall provide, prior to the [*] up to
[*] PC Systems for New Sites or Replacement Fixed Fee Sites in excess of
the [*] set forth in (a) above. Notwithstanding the above, this
obligation shall be reduced by each PC System the cost of which is
reimbursed to SBCL subject to Section IV.K.1 above."
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-3-
<PAGE>
2.6 EXCLUSIVE DEVELOPMENTS AMENDED. Section V.E is replaced in its
entirety as follows:
"E. DEVELOPMENT WORK REQUESTED BY SBCL.
1. SBCL may at any time request that ActaMed perform
additional development work. Subject to the terms of this Section
V.E, SBCL shall pay ActaMed for development services the work product
from which constitutes an Exclusive Development at no higher than the
then industry standard rates for similar services.
a. SBCL shall be entitled to request in writing
that ActaMed perform development services the resulting work from which
shall be for the exclusive benefit of SBCL (an "EXCLUSIVE DEVELOPMENT");
provided that, except as provided in Section V.E.1.b, SBCL shall not be
entitled to more than [*] Exclusive Development [*]. If ActaMed, before
9:00 AM (EST) of the [*] after the date on which such request is
received by ActaMed, delivers to SBCL [*] then, notwithstanding that
SBCL's request specified that the work would be an Exclusive Development,
the work so requested by SBCL shall be a "COMMON DEVELOPMENT." Under no
circumstances shall any SBCL requested development work that is required
for purposes of complying with Applicable Laws, Regulations or any
Regulatory Change constitute an Exclusive Development. Any SBCL
requested work that is (i) classified as a Common Development in
accordance with this Section V.E.1.a, or (ii) required to comply with
Applicable Laws, Regulations or any Regulatory Change, shall not be
counted for purposes of applying the limit on Exclusive Developments
under this Section V.E.1.a.
b. SBCL may request in writing that ActaMed
provide additional development work at any time. Such work shall
result in either a Common Development or Exclusive Development
pursuant to price and terms agreed to by the parties in accordance
with Section V.E.1.e below. Any work classified as an Exclusive
Development in accordance with this Section V.E.1.b shall not be
counted for purposes of applying the limit on Exclusive Developments
under this Section V.E.1.a.
c. ActaMed will not use or license the use of
any Exclusive Development (without regard to whether it constitutes a
SCAN Development or ActaLab Software) other than in support of Lab EDI
Services. Subject to the ownership and license rights under the
License Agreement, both
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-4-
<PAGE>
ActaMed and SBCL shall be entitled to make any use of a Common
Development. The terms of the foregoing two sentences shall survive
termination of this Agreement for any reason. ActaMed may charge SBCL
[*] the work product from which constitutes a Common Development. Any
such charge shall be [*] and shall be separately stated on invoices sent
to SBCL.
d. For purposes of this Section V.E, Exclusive
Developments shall include any Changes made pursuant to Section V.C
and paid for by SBCL by reason of Section V.C.4, to be designated as
Exclusive Developments in accordance with the procedures set forth in
this Section V.E.1.
e. Within [*] days after receiving SBCL's request
pursuant to Sections V.E.1.a or V.E.1.b, ActaMed shall notify SBCL of
ActaMed's prices and terms (including estimated completion date) for
performing such development work, which prices and terms SBCL shall not
unreasonably reject. Within twenty (20) days after receiving ActaMed's
notice, SBCL shall accept or reject ActaMed's prices and terms for
performing the development work. If SBCL provides notice accepting (i)
in respect of requests under Section V.E.1.a, ActaMed's prices and
terms, or (ii) in respect of requests under Section V.E.1.b (A)
ActaMed's prices and terms, and (B) ActaMed's designation of the work as
an Exclusive Development or Common Development, then ActaMed shall
perform such work (or cause such work to be performed) on the accepted
terms, and shall integrate the developed work into the ActaLab Software
or SCAN Developments, as applicable, and offer it as an additional
feature or function of Lab EDI Services, as soon as is reasonably
practicable.
If SBCL provides notice that it does not accept ActaMed's prices and
terms, SBCL and ActaMed shall negotiate in good faith an alternative
arrangement to the mutual satisfaction of the parties. If within [*]
SBCL and ActaMed cannot reasonably agree upon such an alternative
arrangement, then SBCL may engage a third party to perform the
development services for such work, subject to Section V.E.1.f. Work
performed by such a third party shall be (i) an Exclusive Development
without regard to the frequency limitation of Section V.E.1.a, subject
to Section V.E.1.f below, (ii) integrated by ActaMed into the ActaLab
Software or SCAN Developments, as applicable, as soon as is reasonably
practicable, and (iii) offered by ActaMed as an additional feature or
function of Lab EDI Services, as soon as is reasonably practicable.
SBCL and ActaMed shall cooperate in developing acceptance standards
and processes (the "ACCEPTANCE PROCESS") pursuant to which work
prepared by a third party, in accordance with industry standard
practices, shall be (i) reviewed, tested and modified, as necessary,
to conform with ActaMed's professional standards,
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-5-
<PAGE>
the Performance Standards and ActaMed's compliance obligations under
Article VI, (ii) integrated into the ActaLab Software or SCAN
Developments, as applicable, and (iii) offered by ActaMed as an
additional feature or function of Lab EDI Services; provided, SBCL
shall reimburse ActaMed (at no higher than the then industry standard
rates for similar services) for any costs or expenses incurred by
ActaMed in any such testing, integration and offering of an additional
feature or function of Lab EDI Services under this Section V.E.1.e.
f. Any contract between ActaMed and SBCL (or a
third party developer and SBCL) for development of an Exclusive
Development shall allocate ownership of and other rights with respect
to the Exclusive Development, as between ActaMed and SBCL, in the
manner contemplated by the License Agreement and Development
Agreement, including, without limitation, Sections 2.1.4 and 2.3.2 of
the License Agreement.
2. If, at any time, SBCL chooses to contract with
ActaMed for a dedicated services team from ActaMed to handle
development of Changes to the Network, the Licensed Materials, or
SBCL's proprietary systems which are not required to be performed by
ActaMed pursuant to Section V.C and which are not requested pursuant
to Section V.E, ActaMed may elect whether to provide the dedicated
team and, if it so elects, shall do so only on terms and conditions
agreed to in advance by SBCL."
2.7 EXCLUSIVITY PERIOD. Section XIII.C.2 is hereby replaced in its
entirety as follows:
2. At any time prior to [*] ActaMed shall not provide services
to any Other Lab at the SBCL Sites transferred to ActaMed pursuant to
the Purchase Agreement, including without limitation, to install or be
instrumental in [*] located at such sites which [*] for services [*] or
otherwise provide [*]. A full calendar month shall be added to the date
set forth in the preceding sentence for each month after [*] in which
ActaMed, determined as of the first day of each succeeding month, has
failed to complete the development of a fully functional ActaLab
Software (as described in the Development Agreement) and deploy a fully
tested, accepted and operating version of such software at one or more
ActaMed Sites.
3 MISCELLANEOUS.
3.1 ENTIRE AGREEMENT. This Amendment No. 1 constitutes the entire
understanding between the parties with respect to amendment to the Services
Agreement and supersedes all proposals, communications and agreements between
the parties relating to such subject matter.
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.
-6-
<PAGE>
No amendment, change, or waiver of any provision of this Amendment No. 1 will
be binding unless in writing and signed by both parties.
3.2 GOVERNING LAW. This Amendment No. 1 will be governed by and
construed in accordance with the laws of the State of Georgia applicable to
contracts made and performed therein.
3.3 SERVICES AGREEMENT PROVISIONS. All provisions of the Services
Agreement not modified by this Amendment No. 1 shall remain in full force and
effect. Subsections D, E and F of Section XVI of the Services Agreement shall
apply to this Amendment No. 1 as if fully set forth herein.
3.4 COUNTERPARTS. This Amendment No. 1 may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
[INTENTIONALLY LEFT BLANK]
-7-
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Amendment No. 1
to the Services Agreement as of the date set forth above.
ACTAMED CORPORATION
By: /s/
---------------------------------------
Its: President & CEO
--------------------------------------
SMITHKLINE BEECHAM CLINICAL LABORATORIES,
INC.
By: /s/
---------------------------------------
Its: President
--------------------------------------
-8-